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miR-484 Functions as an Onco-miR in Triple Negative Breast Cancer
Nashwa Kabil M.D.
Supervisory Professor: Bulent Ozpolat M.D. Ph.D

Abstract:
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer
(BC), with a poor prognosis with currently used therapies, and thus represents an unmet
therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant
genetic heterogeneity are the major reasons contributing to early relapse and high
mortality rates.

Numerous studies have indicated that microRNAs (miRs) have an

important role in BC progression, invasion, angiogenesis, and metastasis. We analyzed
miRNA expression profiles of BC patient data bases and identified that miR-484 is highly
upregulated in all subtypes of BC patients, with the highest expression in TNBC patients.
miR-484 was found to be associated with significantly shorter patient survival, while
inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility
and invasion, and induced cell cycle arrest and apoptosis. Furthermore, we found that
miR-484 is inversely correlated with levels of HOXA5 in patients’ tumors and
demonstrated that miR-484 directly binds to the 3-untranslated region (3-UTR) of
HOXA5 mRNA to suppress its expression. Moreover, HOXA5 over-expression
recapitulated the effects of miR-484 inhibition. In vivo therapeutic targeting of miR-484
by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5
expression and suppressed tumor growth and progression in orthotopic xenograft mouse
models of TNBC. Thus, our findings provide new insights about the oncogenic role of
miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.
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Introduction

Breast Cancer Statistics
It is estimated that about 1 out of 8 women in the U.S. (about 12.4%) will develop invasive
breast cancer (BC) throughout their lifetime. Over a quarter of a million new cases of
invasive BC are expected to be diagnosed by the end of 2018 in women in the U.S, with
an estimated 41,000 deaths (1). Worldwide, BC still remains a global burden, with the
latest reported statistics by the global cancer project (GLOBOCAN 2012), estimating
more than 1.5 million newly diagnosed cases of BC, and over 500,000 deaths. Despite
the advancement in BC management, it still remains the most common cancer in women,
accounting for more than a quarter of all cancer cases (2). The incidence of BC is higher
in developed countries (western world), while relative mortality is greater in developing
countries (2). This discrepancy can be largely attributed to differences in socio-economic
status, availability of early screening and detection programs, and access for treatment
(2).

The Heterogeneity of Breast Cancer
BC is a highly heterogenous disease, composed of multiple subtypes, with each subtype
displaying specific morphological features, which can account for differences in tumor
behaviors, as well as therapeutic response to treatment (3). Historically, BC has been
classified according to the expression of three molecular markers: estrogen receptor
(ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2
(HER2) (4). These molecules also serve as druggable targets for specific therapies (5).
BC tumors that lack ER, PR, and HER-2 receptors are classified as triple-negative breast
cancer (TNBC); a highly aggressive and metastatic subtype of BC, with poor responses
to targeted therapies (6, 7). Subsequent studies utilizing gene expression-profiling
2
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revealed that BC is highly heterogeneous and subtyping was expanded beyond the
original ER/PR/HER2 classification (4, 8, 9). Other clinico-pathological variables such as,
tumor size, tumor grade, and lymph node status, are also used to predict patient
prognosis and management (10, 11).

Gene expression profiling and intrinsic molecular subtypes
In the era of the human genome project, the emergence of microarrays, and other gene
expression profiling platforms has led to the development of an intrinsic subtyping system
using multiple genes in order to classify BC (4, 8). Perou and colleagues conducted the
first study that classified the molecular subtypes of BC into the following 4 subtypes:
estrogen receptor positive (ER+)/luminal-like, basal-like, receptor tyrosine kinase positive
(HER2/neu+), and normal breast (4). According to Perou and colleagues, most of the
triple-negative breast cancers (TNBCs) were included in the basal-like subtype (4, 12).
Subsequently, Sorlie and colleagues identified five major molecular types, that included
luminal A, luminal B, HER2 over-expression, basal, and normal-like tumors (4, 8, 9). Each
of these subtypes harbors specific histopatholoical features that can affect clinical
progression and treatment outcome (13-18). Other gene signatures were introduced
later, including the PAM50 classification which depends on the expression of hormone
receptors, in addition to proliferation related genes, and genes exhibiting myoepithelial
and basal features (19-21). These markers were found to be clinically significant as
having prognostic value and help in predicting therapeutic outcome (22).
Luminal A tumors (ER+/PR+) are frequently low-grade tumors and respond well to ER
targeted therapies such as tamoxifen and aromatase inhibitors (17, 23). Luminal B
3
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tumors (ER+ with or without HER2+ and Ki67 overexpression) tend to be more aggressive
subtype that may respond to hormonal therapies, but are also frequently associated with
recurrence and poorer response (22, 24, 25). HER2+ tumors (ERBB2/HER2 amplified)
while they are regarded as an aggressive subtype, are sensitive to anti-HER2 therapies
such as monoclonal antibodies (eg. trastuzumab and pertuzumab) or the small-molecule
kinase inhibitor lapatinib (25, 26).
Basal tumors
Basal tumors do not express ER, PR, or HER2R and display expression profiles similar
to basal epithelial cells, as wells as normal breast myoepithelial cells (4). They also have
high expression of basal markers such as keratins 5, 6, 14, 17, and epidermal growth
factor receptor (EGFR), and proliferation related genes (4, 27). These tumors are more
frequently associated with low BRCA1 expression (28) and TP53 mutations (8, 29). Basal
tumors, which account for 60% to 90% of triple negative tumors (13, 30), tend to follow
an aggressive clinical course, with more likelihood to metastasize to distant organs, with
the exception to bone, and lymph nodes (31). Given their lack of expression of hormonal
receptors, basal tumors are not sensitive to anti-hormonal targeted therapeutics, leaving
conventional chemotherapies as their only therapeutic option (32).

4
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Triple Negative Breast Cancer
Characteristics & Risk Factors
Approximately 15% to 20% of all diagnosed BC cases are TNBC. These tumors share
considerable molecular similarities with basal-like cancers

(up to 70% overlap).

However, TNBC and basal subtypes are histo-pathologically and clinically distinct, and
thus these two subtypes are mutually exclusive (33, 34). TNBCs more prevalent in
African-American or Hispanic women of younger age (<40 years) (4, 6, 35). Other risk
factors for TNBC include multiple and early pregnancies, as well as lack of breast feeding
(36, 37). At stage of presentation, TNBCs are mainly poorly differentiated invasive ductal
carcinoma with a tendency to metastasize to the lung and brain (38, 39). However, unlike
other BC subtypes, the correlation between TNBC tumor size and lymph node status is
not clearly defined (40-42). TNBCs have the worse prognosis compared with other BC
subtypes, with an estimated 5 year survival rate of 70% (3). This survival rate is much
lower for patients with advanced metastasis (~12 month survival) (43, 44).
Molecular Heterogeneity of TNBC
TNBCs are a highly heterogeneous subtype of BC that is composed of 6 molecular
subtypes according to the study by Lehman and colleagues. Each subtype displays
distinct oncogenic drivers that can thus be utilized as potential molecular targets. These
subtypes include: basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal (M),
mesenchymal stem–like (MSL), and luminal androgen receptor (LAR). In their study, they
also identified TNBC cell line models representing each subtype to be utilized in targeting
specific oncogenic pathways identified in the gene expression analysis.

These

subclasses were found to display distinct therapeutic responses that correlate with
5
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pathologic complete response (pCR) rates following neoadjuvant chemotherapy (NAC)
(45). For example, BL1 and BL2 subtypes displayed higher expression of cell cycle and
DNA damage proteins, and representative cell lines showed a favorable response to
taxane-based therapies.

BL1 tumors show the most favorable pCR rates (52%)

compared to other subtypes after NAC, whereas BL2 patients display the lowest pCR
(46).

M and MSL subtypes showed higher expression of epithelial-mesenchymal

markers, and growth factor pathways which responded well to a PI3K/mTOR inhibitors
and an Abl/Src inhibitors (7).

Patients with MSL subtype displayed upregulation of

transforming growth factor receptor III (TGFβ-III), a known driver of migration and invasion
(47), and showed moderate pCR rates (between 20-30%) (46).

The LAR subtype

includes patients characterized by androgen receptor (AR) signaling, with frequent
display of positive PI3KCA activating mutations (48). LAR subtype patients are less
responsive to chemotherapy, with a pCR rate of around 10% (46), but display favorable
response to anti-androgen treatments in combination with PI3K inhibitors (48). Finally,
the IM subclass display higher expression of immune response signaling proteins, and
have a moderate pCR of around 30% (46).

6
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Current Therapeutic Strategies for TNBC
Currently, there are no approved targeted therapeutics available for TNBC, although there
are a several drugs in pre-clinical and clinical trials that are being investigated (49, 50).
Taxane based therapies (eg. docetaxel or paclitaxel), anthracyclines (eg. doxorubicin or
epirubicin) and alkylating agents (eg. Cyclophosphamide) are still considered the gold
standard of therapy for TNBC (49). Given that approximately 15-20% of TNBCs harbor
BRCA 1/2 mutations (51), platinum based therapies that affect the DNA repair mechanism
have been proven to be effective in TNBC patients (50, 52). Also other therapeutic
options include poly ADP ribose polymerase inhibitors (PARP inhibitors), Src family
kinase inhibitors, EGFR inhibitors, as well as anti-androgens (50). A small percentage of
TNBC patients, particularly mesenchymal and luminal androgen receptor (LAR) subtypes
have also been shown to benefit from PI3K/AKT/mTOR inhibitors (50). Another emerging
concept in TNBC management is the use of immune checkpoint inhibitors, targeting either
the programmed death (PD)-1 receptor or its ligand PD-L1, in combination with either
cytotoxic chemotherapy or radiotherapy (53, 54).
Drug Resistance in TNBC
TNBC management remains an extensive clinical challenge due to its aggressive course
and poor therapeutic outcome (6, 35, 55, 56), compared with other BC subtypes (57-59).
Substantial tumor heterogeneity is one of the major reasons for the development of drug
resistance, resulting in the selective survival of residual tumor cells that can repopulate
the tumor and result in relapse (60). Other evidence suggests, that some cytotoxic agents
can promote epithelial-mesenchymal-transition (EMT) and or enrich the tumor initiating
cell population to promote metastasis (61).

7
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Due to the lack of effective targeted therapeutics, new interest has emerged in identifying
new molecular targets and development of therapeutic strategies against them in order
to improve TNBC patient survival and prognosis. In recent years, numerous publications
have highlighted the critical role of miRNAs in cancer (62). Extensive research over the
years has shown that micro RNAs (miRNAs) are implicated in all stages of BC (63, 64),
which has rendered them as valuable diagnostic and prognostic markers (65). Recently,
there has been a growing interest in the use of miRNA based therapeutic strategies in BC
(66).
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Role of miRNA in the Pathogenesis of Breast Cancer
The initial discovery of miRNAs was in early 1990s by Ambros and Lee that found that
short non-coding region of lin-4 negatively regulates the expression of lin-14 during larval
development of C. elegans (67). Later that year, lin-4 was shown to bind to the lin-14 3’
untranslated region (3’-UTR) that harbors multiple conserved sequences complementary
to lin-4 (68). As of 2001, these short non-coding RNAs were classified as a new set of
genes called micro RNAs (miRNAs) (69-71).
miRNA Biogenesis & Mechanism of Action
miRNA genes reside in either intergenic, or intragenic (intronic or in exonic) regions within
the genome. They can be transcribed as a single transcript from its own promoter or
several miRNAs can share a promoter and be transcribed as a long polycistronic primary
transcript (72-74).
miRNA are primarily transcribed by RNA polymerase II into a long primary transcript
called pri-miRNA which can have a nucleotide length up to 1kb. This pri-miRNA is
5’capped and 3’ poly-adenylated (72, 75), and then converted into a hair pin structure
around 70-80 nct. called pre-miRNA by ribonucleases III enzyme DROSHA and RNAbinding protein Digeorge Critical Region 8 (DGCR8), also known as Pasha (75).
Subsequently this pre-miRNA is then transported form the nucleus into the cytoplasm by
Exportin 5 (XPO5), to undergo further processing by DICER (RNAse III endonuclease
enzyme) into a double stranded miRNA, which is around 18-25 nct in length (76). This
double stranded structure is then unwound and single strands, composed of a guide
strand and a passenger strand, are then loaded on to the RNA-Induced Silencing
Complex (RISC) to its target mRNA (77) (Figure 1).
9
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Figure 1: Gene silencing mechanisms of miRNAs
This figure is reused with permission and was originally published by I. FernandezPiñeiro, I. Badiola, and A. Sanchez in Biotechnology Advances, 2017.
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miRNAs mainly act by regulating gene expression at the post-transcriptional level
depending on the degree of sequence complementarity between the miRNA and its target
mRNA. They can either lead to mRNA degradation, in the case of perfect
complementarity; or translational inhibition, in the case of imperfect complementarity (78).
The binding of miRNAs and their target mRNAs mainly occurs by interaction between the
3’-UTR of the mRNA with the miRNA seed sequence (∼6–8 nt), which is located near
their 5’ end, and was found to be highly conserved (79). The 3’-UTR of a single mRNA
can bind to multiple miRNAs and any single miRNA can bind to hundreds of targets.
Thus, miRNAs have the ability to regulate many signaling pathways simultaneously (80,
81). The binding between miRNAs and their target mRNAs can be computationally
predicted using a number of highly accurate predictive algorithms, which can then be
experimentally verified (82, 83).

Currently, there over 2600 mature human miRNAs

according to the miRbase database humans [http://www.mirbase.org/].
Although miRNAs mainly act by binding to the 3’-UTR of their target mRNAs, several
other mechanisms have also been proposed as means of their actions. For example,
miRNAs can by bind to the 5’-UTR regions to increase mRNA translation (84, 85), as in
the case of miR-10b, which was shown to bind the 5’-UTR of ribosomal protein mRNA
and increase their translation (85). Other miRNAs, such as let-7 and miR-363, were found
to increase mRNA expression by recruitment of specific micro-RNPs (eg. Argonaute 2
(AGO) and fragile X mental retardation-related protein 1 (FXR1), to the AU rich regions
in the 3’-UTR of their target mRNA (84). Some studies have also suggested that miRNAs
can be translocated to the nucleus to activate the promotor region of their target genes
and increase transcription (86). For instance, miR-551b-3p was found to recruit RNA
11
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polymerase II and the transcription factor Twist related protein 1 (TWIST1) to the signal
transducer and activator of transcription (STAT3) promoter region, to activate its
transcription (86).

Additionally, some miRNAs can localize to

different subcellular

compartments, as in the case of miR-29b, which has a specific hexanucleotide terminal
sequence that directs its translocation to the nucleus (87). Also a few miRNAs can bind
to RNA-binding proteins and thus inhibit their binding with their target (88). Thus, the
mechanism of miRNA-mediated regulation of gene expression is a mutli-facted subject
that requires further exploration.

Role of miRNA in Cancer
The role of miRNA in cancer was first described in 2002, where it was found that the
chromosomal region 13q14, which is frequently deleted in chronic lymphocytic leukemia
(CLL) patients (89, 90), harbors a chromosomal translocation at t(2:13) at a fragile site
resulting in the deletion of the miR-15a/16-1 cluster (91), suggesting their potential role
as tumor suppressors. The following year in a follow up study, miRNAs were mapped in
chromosomal fragile sites, regions of loss of heterozygosity, or regions of amplifications
(92). Furthermore, in 2005, another study reported that the miR 17~92 cluster, induced
by c-MYC, enhances lymphoma in mouse models of B-CLL, suggesting its possible role
as an oncogenic miRNA (93).

These discoveries paved the way for a new era of

biomedical research in deciphering the role of miRNAs in tumorigenesis, resulting in more
than 30,000 publications recorded on PUB MED to date.
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Mechanisms Altering miRNA Expression in Cancer
The aberrant expression of miRNAs in cancer can be attributed to many factors discussed
below (62).
Genetic Regulation: miRNAs can reside within the chromosomal regions that are
proximal to fragile sites, or in regions of loss of heterozygosity, deletions, amplifications,
or translocations. Chromosomal regions that harbor miRNAs involved in negatively
regulating known tumor suppressors (oncogenic miRNAs), may be amplified, resulting in
increased expression of these oncogenic miRNAs and subsequent reduction in the
expression of their tumor suppressor genes (94). On the other hand, miRNAs that inhibit
oncogenes (tumor suppressor miRNAs) are located at chromosomal fragile sites, where
deletion or mutations can decrease their levels, resulting in overexpression of their target
oncogenes (94).

Such is the case for miR15a/16-1, which were found to be

deleted/translocated in the majority of CLL patients (91), and were later revealed to target
the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in CLL (95).
Epigenetic Regulation: The presence of DNA-binding factors can affect the promoter
regions of miRNA genes. This can result in the downregulation of miRNA genes by hyper
methylation or histone deacetylation of the promoter regions (96). For example, the miR9-1 gene in BC is downregulated due to hyer-methylation of its promoter regions (97).
Other means of epigenetic regulation include histone deacetylation and tri-methylation,
as in the case of miR-29 in B-cell lymphoma (98). On the other hand, histone acetylation
can lead to the activation of miRNA genes, such as that of miR-224 in hepatocellular
carcinoma (99). Other miRNAs can be activated by transcription factors acting at their
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promoter region. For example, the tumor suppressor p53 was found to bind and activate
the promoter regions of the miR-34a (100).
Regulation of miRNA Biogenesis/Processing: miRNAs expression levels can also be
regulated by factors that affect their biogenesis or processing at multiple levels (101). For
example, miRNA biogenesis proteins such as DROSHA, DICER, DGCR8, TRBP, XPO5
and AGO can be affected by genetic mutations, post-translational modifications, or
binding to regulatory proteins, which can ultimately affect miRNA expression levels (102).
Additionally, single nucleotide polymorphisms (SNPs) in a miRNA gene may alter miRNA
processing efficiency by changing its stem–loop structure (101).
Given that one miRNA can have up to several hundred mRNA targets, aberrantly
expressed miRNAs in cancer may affect multiple transcripts and hence significantly
impact numerous cancer signaling pathways (103). For example, factors that lead to
increased expression of miRNAs that are frequently over-expressed in cancer would lead
to enhanced silencing of tumor suppressor genes. Consequently, this may promote
tumor formation by increasing cell proliferation, invasiveness, angiogenesis, or
suppressing apoptosis.

On the other hand, under expression of tumor suppressor

miRNAs in cancers could also promote tumorigenesis through upregulation of their
oncogenic target mRNAs (104) (Figure 2).
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Figure 2: miRNAs can function as tumor suppressors or oncogenes
This figure is reused with permission and was originally published by Aurora EsquelaKerscher, Frank J. Slack in Nature Reviews Cancer, 2006.
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MicroRNAs in Breast Cancer
Several platforms have been developed to profile the global expression of miRNAs in
normal or diseased tissues. In the context of cancer, these profiling studies have been
used to aid in tumor classification and the assessment of diagnosis and prognosis (62).
Iorio and colleagues, in 2005, were the first to describe a specific miRNA signature pattern
that were differentially expressed in normal vs. BC tissue, and was correlated with tumor
grade, disease stage, vascular invasion, proliferation index, and hormone receptor
expression (105).

Subsequently, several studies revealed that aberrantly expressed

miRNAs are able to regulate many process in breast carcinogenesis, thereby acting as
either oncogenic or tumor suppressor miRNAs (106). In BC, miRNAs have been shown
to regulate many processes such as cell cycle progression, apoptosis, angiogenesis,
epithelial-mesenchymal transition, metastasis, and drug resistance (64).

Oncogenic miRNAs in Breast Cancer
Micro RNAs have been demonstrated to be key modulators in controlling the primary
tumor growth, as well as in promoting the metastatic process, and modulating the
interaction of the tumor with its microenvironment (107, 108). Some of the well described
examples of oncogenic miRNAs in BC are discussed below and are listed in Table 1.
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miR-21:
Among the differentially expressed miRNAs that were shown to be upregulated in BC
patients and speculated to be oncogenic was miR-21, which was later one of the most
extensively researched miRNAs with oncogenic properties.

Some of its oncogenic

properties to promote BC cell survival and proliferation may be attributed to targeting
tumor suppressors such as phosphatase and tensin homolog (PTEN) (109), programmed
cell death 4 (PDCD4) (110) and tropomyosin 1 (TPM1) (111). Additionally, the clinical
significance of miR-21 in BC was demonstrated by studies that found it to be associated
with advanced clinical staging, lymph node status, and worse prognosis in BC patients
(112, 113).
miR-10b:
miR-10b was shown to be an oncogenic driver of BC, by promoting migration and invasion
in metastatic BC cells. Moreover, it was also shown to initiate invasion and metastasis in
non-metastatic breast cells. miR-10b expression is enhanced by the transcription factor
TWIST1, which binds to its promoter region. miR-10b acts by binding and inhibiting the
expression of HOXD10, which then enhances the expression of the pro-metastatic gene,
Ras homolog gene family member C (RHOC) protein (114). miR-10b was also shown
to be a miRNA of clinical significance as it was found to be positively correlated with BC
staging, histological grading, and lymph node metastasis (115). Additionally, miR-10b
was shown to target E-cadherin in metastatic BC cells to promote cell invasion (116).
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miR-155:
miR-155 is another miRNA that was found to be frequently up-regulated in breast tumor
tissue and was found to be associated with clinicopathologic markers, BC subtype, and
poor survival rates (105, 117, 118) . miR-155 was found to act via targeting and
downregulating the expression forkhead box O3 (FOXO3a) to enhance tumor cell
sensitivity to chemotherapy and mediate apoptosis (119). Other studies suggested that
miR-155 promotes BC oncogenesis by targeting suppressor of cytokine signaling 1
(SOCS1), leading to the activation of the JAK/STAT3 pathway. In that study, miR-155
expression was found to be induced by inflammatory cytokines such as IL-6 and INF-γ,
suggesting its possible relationship to inflammation in cancer (120). Additionally, miR155 was shown to target caspase-3 in activated macrophages to promote their survival
in the inflammatory response (121).
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Table1: Oncogenic miRNAs in Breast Cancer

Oncogenic
miRNA

miR-21

miR-155

Target
TPM1,
PDCD4,
TIMP3,
PTEN
FOXO3a,
SOCS1,
caspase-3,
TP53INP1

Cancer Related
Events

References

Cell proliferation,
Apoptosis,
Invasion

(110, 111,
122, 123)

Cell proliferation,
Apoptosis, Cell
cycle progression
Invasion,
Migration,
Metastasis
Cell motility,
Invasion,
Angiogenesis,
Metastasis
Cell proliferation,
Cell cycle
progression,
Angiogenesis,
Metastasis
EMT, Migration,
Invasion,
Metastasis

(119-121,
124)

miR-10-b

HOXD10, Tiam1

miR-9

E-cadherin

miR-27a

HOXO1,
ZBTB10

miR-181a

Bim

miR-182

RECK, MIM,
FOXO1

Cell proliferation,
Invasion

(129, 132)

miR-221/222

TRPS1,
ADIPOR1,
p27Kip1

EMT

(133-135)

miR-373/520c

CD44

Migration,
Invasion,
Metastasis

(136)
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(127)

(128-130)
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Introduction

Tumor Suppressor miRNAs in Breast Cancer
Let-7 family:
One of the well characterized examples of tumors suppressor miRNAs in BC is the let-7
family. Several groups have reported that the let-7 family are differentially expressed in
BC, as well as in other tumors (137-139).

Let-7, tumor suppressor microRNA was

originally discovered in C. elegans, where it was found to regulate cell differentiation and
cell cycle (140). This family has been shown to act as tumor suppressor miRNAs by
targeting critical oncogenes such as RAS, high-mobility group AT-hook 2 (HMGA2), cMyc, and caspase-3 (141-144), as well as several genes involved in

stem cell

maintenance (145).
miR-34 family:
Another well characterized tumor suppressor miRNA family in BC is the miR-34 family.
The miR-34 family is composed of 3 members: miR-34a, which is encoded by its own
gene from chromosome 1p36, and miR-34b/c which are co-transcribed from a shared
locus on chromosome 11q23 (146). miR-34a is the most extensively studied member in
cancer and was found to inhibit many different oncogenic processes relating to tumor cell
differentiation, proliferation, migration, and invasion by targeting BCL-2 and SIRIT1 (147,
148); and induce apoptosis and cell cycle arrest (100).

Previous studies have shown

that miR-34a js transcriptionally activated by tumor suppressor p53, and thereby
contributes to p53 mediated downstream effects on cell cycle arrest and induction of
apoptosis, by targeting c-MYC, CDK6, and c-MET (146). Other studies have also shown
that miR-34a targets NOTCH, epithelial-mesenchymal transition (EMT), and transforming
growth factor beta (TGF-β) signaling pathways, as well as elongation factor 2 kinase
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(EF2-K) and forkhead box protein M1 (FOXM1) axis, WNT/β-Catenin pathways (146, 149,
150).

miR-200 family:
There are five members of the miR-200 family, which are organized into two clusters.
Cluster 1 is composed of miR-200a, miR-200b, and miR-429, located on chromosome1,
while, cluster 2 is composed of miR-200c and miR-141 (miR-200c/141) located on
chromosome 12 (151). Previous studies have shown the miR-200 family is involved in
regulating EMT by zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2, which are
transcriptional repressors of E-cadherin, and thereby maintaining an epithelial like state
(152-154). On the other hand, other studies have shown the existence of a reciprocal
feedback loop where ZEB1 and ZEB2 also act by repressing miR-200 transcription (155,
156).
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Table 2: Tumor Suppressor miRNAs in Breast Cancer

Tumor
Suppressor
miRNA
Let-7 family

miR-34 family

miR-200 family

miR-145

miR-205

miR-30 family

miR-335

Cancer Related
Events

Targets

References

Stemness, Cell
H-Ras, HMGA2,
motility, Migration,
PAK1, DIAPH2
Invasion

(157-159)

Cell proliferation,
Migration,
Invasion, EMT,
Cell cycle
progression,
Apoptosis

(147, 148)
(146, 160,
161)

BCL-2, SIRIT1
c-MYC, CDK6,
c-MET,
NOTCH1, EF2K, FOXM1
ZEB1, ZEB2,
HER3, Sec23a,
SIRT1

EMT, Stemness,
Metastasis

IRS-1, ER-α,
RTKN, MUC1,
OCT4, N-Ras,
VEGF-A

Cell proliferation,
EMT, Invasion,
Metastasis,
Angiogenesis

ZEB1, ZEB2,
HER3, VEGF-A

EMT, Cell
proliferation,
Invasion,
Stemness

MTDH, FOXD1,
AVEN, VIM,
Eya2, Vimentin,
KRAS, MAPK,
TWFI

Cell proliferation,
Cell cycle
progression,
Apoptosis,
Invasion, Chemosensitivity

SOX4, tenascin
C, ER-α, IGF1,
RSP1, ID4

Cell proliferation,
Apoptosis,
Metastasis
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(176)
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miRNAs as Diagnostic & Prognostic Markers in Breast Cancer
Recent evidence has suggested that circulating miRNAs are present in several body
fluids including blood, serum, saliva, urine, and breast milk (185-187).

Circulating

miRNAs are either free or packaged into vesicles such as exosomes, apoptotic bodies,
or incorporated with high density lipoproteins, or AGO proteins (188). Thus circulating
miRNAs are stable, easily detected by non-invasive measures, making them ideal
biomarkers for early cancer detection and predictors of therapeutic outcome (65).

Studies have indicated that miRNAs may be valuable diagnostic markers for early
detection of BC. One of the most extensively studied miRNAs in cancer is miR-21, which
has been shown in numerous studies to be a useful diagnostic biomarker for BC, as it is
significantly overexpressed in either plasma/serum or tissue samples of BC patients
compared to normal healthy volunteers (189-192). Furthermore, miR-21 proved to be a
highly reliable biomarker, displaying higher sensitivity than other well characterized
markers, such as clinical cancer antigen 15-3 (CA153) and carcinoembryonic antigen
(CEA) in BC diagnosis (191). Other extensively studied oncogenic miRNAs for BC
diagnosis include miR-155 (193-195) and miR-18a (196, 197).

miRNAs could also serve as prognostic tools in BC whereby their expression can predict
patient survival and treatment outcome. For example, high miR-21 expression levels
were shown to be associated with reduced disease-free survival (DFS) and overall
survival (OS), as well as clinical staging and lymph node metastasis in BC patients (112,
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198, 199). Furthermore, miR-21 was also shown to have prognostic value as it was
demonstrated to be highly expressed in the bone marrow of BC patients (200).

miRNAs as Markers for Therapeutic Response
miRNAs could also be predictive of therapeutic outcome, whereby their expression levels
could indicate either sensitivity or resistance to treatment. For instance, high expression
of miR-210 in tissues has been associated with poor patient survival and prognosis in
ER+ tamoxifen-treated BC patients (201). Similarly, high levels of miR-210 was also
found to be correlated with trastuzumab resistance in HER2+ breast tumors (202).

miRNAs as a Novel Class of Targeted Therapeutics
Give the critical role of miRNAs in carcinogenesis, and their ability to simultaneously
regulate many targets/pathways, a growing interest in recent years has been in utilizing
miRNA based therapies as a therapeutic modality in cancer (203). This can be achieved
by either restoring tumor suppressive miRNAs (miRNA mimetics) or by inhibition of
oncogenic miRNAs (miRNA inhibitors) (203).
Restoring Tumor Suppressor miRNAs in Breast Cancer
Restoring the expression and function of tumor suppressor miRNAs can be achieved by
miRNA mimics which are synthetic oligonucleotides that can also be chemically modified
(2′-O′methoxy) to increase their stability (204). By replacing the lost or suppressed tumor
suppressor miRNAs, these synthetic molecules can be loaded into the RISC complex to
achieve downstream target inhibition (203). Several studies have validated the efficiency
of miRNA replacement therapies in many in vitro and in vivo models of cancer (203),
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including BC (205, 206). For example replacement of the tumor suppressor Let-7 miRNA
by lenti-viral system lead to decrease cellular proliferation, self-renewal, and metastasis
of BC cells (207). Another example is the replacement of miR-145 and miR-205 , which
were found to restore functional BRCA1 gene in BC (208). Furthermore, down-regulated
tumor suppressor miRNAs such as miR-205, miR-126, miR-335, and miR-451 can be
restored through miRNA replacement therapy (157, 209, 210).

Targeting oncogenic miRNAs in Breast Cancer
miRNA inhibitors are single stranded oligonucleotides that are complementary to
endogenous miRNAs and have the ability to bind/sequester miRNAs and thereby prevent
their processing by the RISC complex. Some examples of miRNA inhibitors include: antimiRNAs (AMOs), locked nucleic acids (LNAs), antagomirs, and miRNA sponges (203).

Anti-miRNA oligonucleotides (AMOs) are single-stranded, anti-sense oligonucleotides,
that can bind to their selected miRNA by Watson Crick interaction, and thus prevent the
miRNA from binding to its target (211).

AMOs have shown to be successful in

suppressing miR-21 levels in BC cells both in vitro and in vivo. For instance, the use of
anti-miR-21 oligonucleotides were found to suppress both MCF-7 cell growth in vitro and
tumor growth in vivo in xenograft mouse models. Furthermore, the effect of miR-21
inhibition in decreasing cell growth was also associated with an increase in apoptosis, in
part by downregulation of the anti-apoptotic protein Bcl-2 (212).
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AntagomiRs are chemically modified synthetic oligonucleotides that are complementary
to miRNAs and can effectively compete with miRNAs for their target mRNAs with a
stronger binding affinity (213). AntagomiRs are modified by the addition of 2’-O-methoxy
group on the ribose residues, partial replacement of phosphodiester bonds to
phosphorothioate, and the addition of a cholesterol motif at 3′ end (213). The 2′-Omethoxy and phosphorothioate modifications help improve their bio-stability, whereas the
cholesterol conjugation increases their cell distribution and permeation (214). It has been
demonstrated that antagomiR-21 can reduce cell proliferation and lead to induction of
apoptosis in BC cells (212, 215).

Additionally, miR-21 antagomiRs were found to

enhance the response to trastuzumab in resistant BC cells by upregulating PTEN (216).

Locked nucleic acids (LNAs) are modified anti-sense oligonucleotides where the ribose
moiety is locked in a C3’-endo conformation by an extra methylene bridge (217). LNAs
against miR-10b were found to be effective in inhibiting BC metastasis (218). LNAs
packaged in nano-liposomes were also found to prevent lymph node metastasis in
orthotopic MDA-MB-231 tumor models (219).

Additionally, the use of LNA miR-21

successfully reduced miR-21 expression levels as well as proliferation of BC cells (215).

A miRNA sponge is a construct that encodes a mRNA containing multiple complementary
binding sites in its 3′-UTR for the miRNA of interest (220). Sponges can bind from 2-7
specific seed sequences of the miRNAs of interest, and have the ability to bind to miRNAs
from the same family (221). Previous studies have shown that miR-9 sponges results in
more than 50% reduction of miR-9 activity in 4T1 mammary tumor cells (127). In addition,
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miR-10b sponges effectively reduced cell growth, migration, and invasion in MDA-MB231 and MCF-7 BC cell lines, along with upregulating the expression of the miR-10b
target HOXD10 (222) .

Current Challenges in microRNA Delivery
Despite the recent advances in the field of miRNA-based therapies, there are still many
challenges to overcome in order to ensure safe and effective miRNA delivery in vivo.
These obstacles include enzymatic degradation by nucleases, rapid renal clearance, as
well the development of immune toxicities, and off-target effects (223, 224). Thus, the
use of miRNA modulators is limited due to their poor bioavailability, stability, and tissue
permeability (223). Therefore, several miRNA delivery systems have been engineered
using viral or non-viral vectors in order to overcome these hurdles (225). Although viral
based vectors; made of either lentiviruses, adenoviruses, or adeno-associated viruses;
have been shown to efficiently deliver miRNA modulators in vivo; their use is limited by
their immunogenic effects (226). Hence, the use of non-viral vectors may offer a safer,
less toxic alternative (227). One increasingly popular approach for miRNA delivery is the
use of nano-carriers which are biocompatible and biodegradable carriers, that are highly
versatile with the ability to modify their size and surface in order to enhance tumor-specific
delivery (227). Nano-carriers (1-1000nm) can be formed of inorganic materials such as
gold or silica; or organic materials such as polymers or lipids; (228, 229) and offer the
advantage of increased payload stability, and bioavailability, as well as selective
accumulation at the tumor site due to the enhanced permeability and retention effect (228,
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230). Additionally, nano-carriers can be modified to express specific ligands for receptors
on tumor cells (231).

Figure 3: miRNA mechanism and modulation. Canonical biogenesis and
processing of miRNAs and mechanism of RNAi-regulated gene silencing.
This Figure is reused under the terms of the CC-BY-NC-ND license agreement
(http://creativecommons.org/licenses/by-nc-nd/4.0/), and originally published by Maitri Y.
Shah, Alessandra Ferrajoli, Anil K. Sood, Gabriel Lopez-Berestein, George A. Calin in
EBio Medicine, 2016. doi:10.1016/j.ebiom.2016.09.017.
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First miRNA-Based Clinical Trials
Due to the great promise in utilizing miRNAs as therapeutic agents, there are now several
ongoing clinical trials on miRNA based therapies in many cancers. For example, the
locked nucleic acid (LNA) against miR-122 Miravirsen (SPC3649), developed as
treatment of hepatitis C virus (HCV), was found to safe and well tolerated in phase I
clinical trial, and effective in Phase II trials, with a significant reduction in HCV RNA levels
(232).

Another noteworthy example is the replacement therapy of the tumor suppressor miR34a by a liposomal mimetic (MRX34), which was evaluated in the first-in-human, phase I
study, in patients with advanced solid tumors, including hepatocellular carcinoma,
melanoma, and renal cell carcinoma (233). However, this clinical trial was halted by
miRNA Therapeutics due to multiple immune-related severe adverse effects that were
observed (http://www.businesswire.com). Therefore, dose optimization for miRNA based
strategies is highly warranted in order to prevent potential adverse events.

With the great promise that miRNA based therapies hold, there are still some obstacles
that need to be overcome such as improving their safety, modes of delivery, and their
therapeutic efficacy before their translation from the bench to the clinic. However, a
deeper understanding of the biological role of miRNAs could pave the way for a new era
in personalized medicine.
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Hypothesis & Aims:
TNBCs represent a significant clinical challenge that is largely attributed to lack of
effective targeted therapeutics, significant tumor heterogeneity, and poor response to
conventional chemotherapies (6). Therefore, better understanding of the biology of the
disease and identification of novel molecular targets is crucial for the development of
highly effective therapies to eradicate TNBC and improve patient survival. Given the role
of miRNAs in initiation, progression, metastasis, and drug resistance in various human
cancers including BC, identification of clinically significant miRNAs that are involved in
TNBC growth and progression is critical for better understanding of the complex biology
of this cancer and for development of miRNA based strategies (106, 225). Recent studies
have shown that miRNA 484 was among seven miRNAs that were correlated with OS
amongst various clinical and molecular subtypes of invasive ductal carcinoma patients
(234). Furthermore, miR-484 was also found to be significantly highly expressed in serum
of early BC patients compared to healthy volunteers, suggesting that it may serve as an
early diagnostic biomarker (235). However, the role and mechanism of action of miR-484
in TNBC has not been previously elucidated. In light of this, we embarked on identifying
clinically significant miRNAs using the The Cancer Genome (TCGA) database, and we
identified miR-484, which we found to be clinically and prognostically significant and
correlated with poor overall survival (OS) in BC (Fig. 4), supporting the previous findings.
We further analyzed miR-484 expression profiles in all clinical BC subtypes including,
ER+, ER-, HER2+, and TNBC, which we found to have the highest expression compared
with normal breast tissues (Fig. 5). Additionally, we found that miR-484 expression is
significantly higher in basal subtype of BC compared to non-basal subtype and matched
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normal breast tissues (Fig. 6). Furthermore, we screened a panel of TNBC cells lines for
basal miR-484 expression, and found that miR-484 was upregulated in all of our TNBC
panel (2-10 folds) compared to normal mammary epithelial cells (MCF-10A) (Fig. 7). .
Overall Hypothesis:
Thus, based on our preliminary data, as well as the recent findings, our overall hypothesis
is that miR-484 acts as onco-miR to promote tumor growth & progression in TNBC.

We tested this hypothesis with the following specific aims:

Aim 1: Determine the functional role of miR-484 in TNBC cells in vitro.
Aim 2: Determine the mechanism of action of miR-484 in TNBC cells.
Aim 3: Determine the role of miR-484 in TNBC tumorigenesis in orthotopic TNBC mouse
models.
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Low miR-484
High miR-484

Figure 4: High miR-484 expression is associated with shorter overall survival in
breast cancer patients. Kaplan-Meier Survival curves analysis showing high miR-484
expression is associated with shorter overall survival rate in BC patients compared with patients
with low miR-484 expression (n=602) (p≤0.001).

32

Introduction

Figure 5: miR-484 expression is significantly higher in TNBC subtypes compared
to non-TNBC subtypes and normal tissues. The number of patients is listed at the bottom
of the graph (p≤0.001).
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Figure 6: miR-484 expression is significantly higher in basal subtype of BC
compared to non-basal subtypes. The number of patients is listed at the bottom of the graph
(p≤0.001).
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Figure 7: miR-484 levels are upregulated in TNBC cells. Expression levels of miR-484
in TNBC cell lines and normal breast epithelial MCF-10A cells by qRT-PCR. Data was normalized
to the expression of U6 as an endogenous control and represent means ± SDs of three
independent experiments.
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CHAPTER II:
METHODS
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Cell Lines and Culture conditions
TNBC cell lines (MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468, MDA-MB361, BT-549, BT-20, BT-483, HCC-1937, and SUM-149) and human mammary epithelial
cell lines (MCF-10A, HMEC) and) were purchased from the American Type Culture
Collection (Manassas, VA). TNBC cells were cultured in Dulbecco's modified Eagle's
medium (DMEM/F12), with the exception of HCC-1937, which was cultured in RPMI1640,
and all media were supplemented with fetal bovine serum (FBS 10%) and a
penicillin/streptomycin (100-U/ml) (Sigma). MCF-10A cells were cultured in DMEM/F12
media with the addition of horse serum (5%), insulin, hydrocortisone, epidermal growth
factor, and cholera toxin. Cultured cells were kept in a water-saturated incubator (95%
air–5% CO2) at a temperature of 37°C.
The Cancer Genome Atlas (TCGA) and Bioinformatics Analysis
Statistical analyses were performed in R (version 3.4.1) (http:///www.r-project.org/) and
the statistical significance was defined as a p-value less 0.05. We downloaded patient
clinical information for the TCGA patients with breast invasive carcinoma from cBioPortal
(http://www.cbioportal.org/).

For

‘reads_per_million_miRNA_mapped’

the
values

miRNA-Seq
for

the

data,
mature

we

derived

the

form

hsa-miR-484

(MIMAT0002174) from the “Isoform Expression Quantification” files from Genomic Data
Commons Data Portal (https://portal.gdc.cancer.gov/).

The log2-transformation was

applied to the data. We analyzed total of 914 invasive BC cases with miRNA data and
clinical information available. For 93 cases matched, normal solid tissue was available.
To determine the expression difference for miR-484 among normal and tumor tissue of
different subtypes, we first employed a Shapiro-Wilk test and verified that the data does
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not follow a normal distribution. The Kruskal-Wallis non-parametric test was applied to
determine the relationship between miRNA expression and tissue type. Data is
represented as box and-whisker plots (Box plot represents first (lower bound) and third
(upper bound) quartiles, whiskers represent 1.5 times the interquartile range). Univariate
Cox proportional hazards model was fitted to evaluate the association between OS and
covariates including miR-484 expression levels (dichotomized at the tertiles to create
groups that are “high” or “low”) and available clinical variables (age at diagnosis, stage).
Stage, age, and miR-484 were statistically significant factors in the univariate Cox
proportional hazards models, and were included in the final multivariable analysis of OS.
miR-484 was an independent factor (HR= 2.02, CI(95%)=(1.23, 3.31), Wald test p-value=
0.005). In order to visualize the survival difference the Kaplan-Meier plots were generated
for “low” (first tertile) and “high” (last tertile) miR-484 groups. We applied a Spearman's
rank-order correlation test to measure the strength of the association between HOXA5
expression and miR-484 expression. We imposed a cut-off of functional relevance on the
Spearman correlation coefficient in absolute value of 0.2 based on previously published
methodology (236).
miRNA Transfection
MDA-MB-231, MDA-MB-436, and BT-20 cells were plated at a density of 1.5 × 105
cells/well in six-well plates and treated with either miR-484 (100 nM), or control miRNA
mimic or inhibitor (100 nM) (Ambion) with the addition of HiPerFect transfection reagent
(Qiagen) in Opti-MEM serum free media according to the manufacturer’s instructions.
After 6 h of transfection, cultured media was substituted with DMEM supplemented with
10% FBS for up to 48 h.
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Cell viability
Cell viability of MDA-MB-231, MDA-MB-436, BT-20, and MCF-10A cells was analyzed
using

MTS

assay

[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H tetrazolium] as previously described (237). Cells were seeded in a
density of 1 to 2 × 103 cells/well in 96-well plates. After overnight incubation, the cells
were treated with miR-484 inhibitor or control inhibitor miRNA (Ambion). We determined
the cell viability by measuring the optical density at 490-nm wavelength in a VMax kinetic
enzyme-linked immunosorbent assay microplate reader (Molecular Devices) at 24, 48,
and 72 hours
Colony formation assay
The effect of miR-484 on TNBC cell proliferation was evaluated by the clonogenic assay.
MDA-MB-231, MDA-MB-436, and BT-20 cells were seeded at low density (500 cells/well)
in 12-well plates. After overnight incubation, the cells were treated with either control
inhibitor miRNA or miR-484 inhibitor and cultured for approximately 10-14 days. Colonies
were stained with crystal violet, and quantified with Image J software (National Institutes
of Health, Bethesda, MD). Each experiment was independently triplicated.
Cell motility and invasion assays
Cell motility and migration was analyzed by an in vitro wound healing assay. TNBC cells
(MDA-MB-231, MDA-MB-436, and BT-20) were plated at a density of 1.5 × 105 cells/well
in six-well plates. The following day cells were transfected with the control miRNA
inhibitor or miR-484 inhibitor. After 48h, as the cells reached ~80% confluence, a single
scratch was made, and cells were imaged at 0h and subsequent 12h time points, using
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a phase contrast microscope (Nikon Eclipse TE-200-U) to measure the wound width.
Wound healing was measured as percentage open area of the wound by Image J
software. All experiments were independently repeated three times.
We evaluated TNBC cell invasion utilizing matrigel coated transwell inserts (Corning).
After 48h transfection with either miR-484 inhibitor or control miRNA inhibitor MDA-MB231, MDA-MB-436, and BT-20 cells (4 × 104) were collected in serum free medium and
added to the upper chamber of the transwell inserts, allowing cell invasion toward the
lower chamber which contains serum positive media (10% FBS). After 24h, invaded cells
at the bottom of the inserts were fixed, stained with Hema 3 (Thermo Scientific), and
counted using a light microscope (Nikon Eclipse TE-200-U) at 10X magnification.
Invaded cells were counted in five fields per slide and all experiments triplicated.
Cell cycle analysis
TNBC cells were transfected as previously described with miRNA inhibitors or control
inhibitor. After 48h treatment, cells were collected and washed in PBS and fixed in 75%
ethanol overnight. The following day cells were centrifuged and resuspended in PBS
containing 50 μg/ mL propidium iodide (PI) and 100 U/mL of RNAse A. Samples were
incubated in the dark for 30 minutes at a temperature of 37ºC prior to flow cytometry
analysis. The number of cells in each phase of the cell cycle was determined by FlowJo
Software. All experiments were independently triplicated.
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Analysis of apoptosis
Apoptosis was assessed by an Annexin V assay. TNBC cells were seeded in 6 well
plates (1.5 X105/well) and transfected with either control inhibitor or miR-484 inhibitor
(100nM) for 48 h. Cells were then collected and stained with Annexin V/propidium iodide
(PI) according to the manufacturer’s protocol (BD Pharmingen FITC–Annexin V kit, San
Diego, CA).

We determined the number of apoptotic cells by flow cytometry using

CellQuest Pro software (BD Biosciences). This assay is based on the binding of Annexin
V to membrane phospholipids of the apoptotic cells that are translocated from the inner
to the outer the membrane in apoptotic cells (238). Apoptosis was also confirmed, by
detecting the cleavage of caspase-3, caspase-8, caspase-2, and PARP by Western
blotting.
Reverse phase protein array (RPPA)
We performed the RPPA analysis at the Functional Proteomics RPPA Core Facility of
The University of Texas MD Anderson Cancer Center according to the method described
previously (239). MDA-MB- 231 cells were plated in six well plates at a density of 1.5 ×
106 cells/well and transfected with either miR-484 mimic or control miRNA (100 nM) for
48h. Cells were collected in 100 μl of lysis buffer supplemented with protease and
phosphatase inhibitors (Roche Applied Science). Samples were centrifuged at 14,000 X
g for 30 minutes at a temperature of 4°C. Supernatants were collected, and total proteins
concentration was determined by Pierce BCA protein assay kit. Protein concentrations
were adjusted to a concentration of 1.0 μg/μl by the addition of lysis buffer. 4XSDS
Sample Buffer was mixed with β‐mercaptoethanol (β‐Me) at a ratio of 9:1. Cell lysates
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were then mixed with 4× SDS sample buffer + β-Me mixture at a ratio of 3:1. Samples
were boiled for 5 minutes and stored at -80ºC prior to submission to the RPPA Core
Facility.
Luciferase reporter assay
pEZX-MT06 miRNA reporter vectors containing the binding sites for miR-484 in the 3’UTR of HOXA5 and the luciferase gene (GeneCopoeia) were transfected into MDA-MB231 and MDA-MB-436. As a control for target specificity, we transfected pEZX-MT06
miRNA reporter vectors containing one point mutation at the miR-484 binding site
(GAGCCTG> GCTACAG) into MDA-MB-231 and MDA-MB-436 cells. Cells were plated
(5×104 cells/well) in a 24-well plate and incubated overnight. The following day cells were
co-transfected with the pEZX-MT06 vector (200 ng) and either 100 nM miR-484 mimic or
control miRNA. After 48h, firefly luciferase activity was determined by utilizing Luc-Pair
miR Luciferase Assay (GeneCopoeia) and measurements were normalized to Renilla
luciferase activity.
Western blot analysis
TNBC cells (MDA-MB-231, MDA-MB-436, and BT-20) were treated with miR-484 inhibitor
or control inhibitor miRNA (100nM) and cells were collected after 48h transfection.
Lysates were prepared in lysis buffer supplemented with protease and phosphatase
inhibitors and samples were centrifuged at 14,000 × g for 30 min at a temperature of 4°C.
Supernatants were collected and analyzed for protein concentration by using the Pierce
BCA protein assay kit (Thermo Scientific). Protein samples (40µg) were separated by
SDS-PAGE on a 4%–15% gradient polyacrylamide gels (Bio-Rad), and subsequently
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electro-transferred to polyvinylidene difluoride membranes.

Membranes were blocked

with 5% milk in TBST, rinsed, and then incubated with primary antibodies overnight at
4ºC. The following day membranes were rinsed and incubated with their corresponding
HRP-conjugated secondary antibodies. GAPDH expression levels were detected as
loading control. Antibodies used in this study are listed in the appendix in Table 3.
HyGLO Chemiluminescent Reagent (Denville Scientific) was used to detect the
expression levels of the selected proteins and immunoblots were imaged by Fluor Chem
8900 imager and using Alpha Imager software (Alpha Innotech). All experiments were
independently triplicated.
RNA isolation and quantitative real time polymerase chain reaction (qRT-PCR)
For mRNA and miRNA detection, first we isolated total RNA using the miRNeasy Mini Kit
(Qiagen) according to the manufacturer’s protocol. Subsequently, RNA concentration
and purity was determined spectrophotometrically (260 and 280 nm UV absorbance) by
Epoch microplate reader (BioTek Instruments). For miRNA expression, 1µg of total RNA
was reverse transcribed to complementary DNA (cDNA) using the qScript microRNA
cDNA Synthesis Kit (Quanta BioSciences) according to manufacturer’s instructions. miR484 expression was detected by using miRNA primers (Quanta Bio Sciences) by
quantitative real time polymerase chain reaction (qRT-PCR) and utilizing the PerfeCTa
microRNA Assay Kit (Quanta Bio Sciences). The expression levels of miR-484 were
normalized to expression levels of U6 small nuclear RNA (RNU6; Quanta Bio Sciences),
as an endogenous control.
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For HOXA5 mRNA quantification, first we reverse transcribed total RNA to cDNA using
Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific) following the
manufacturer’s instructions. Then HOXA5 gene expression was measured with the iQ
SYBR Green Supermix qPCR Kit (Bio-Rad). GAPDH expression levels were determined
as endogenous control. The sequences of the forward and reverse primers for HOXA5
and GAPDH are listed in the appendix in Table 4. Relative expression levels were
analyzed by the comparative threshold cycle (2-ΔΔCt) method.
HOXA5 gene overexpression
MDA-MB-231 cells were transfected with lentiviral plasmids containing the specified
lentiviral vector for HOXA5 (NM_019102.3) with the CMV promoter (LPP-F0180-Lv105;
GeneCopoeia, Rockville, MD) or the mock vector (LPP-NEG-Lv103; GeneCopoeia)
according to the manufacturer’s instructions.

HOXA5 protein expression was then

verified by Western blotting.
Orthotopic xenograft TNBC tumor models
For our animal study we obtained female nude athymic mice from M.D. Anderson Cancer
Center. We performed our animal study according to an experimental protocol approved
by the M.D. Anderson Institutional Animal Care and Use Committee. TNBC cells (MDAMB-231 and MDA-MB-436) were injected into the mammary fat pad of each mouse at a
density of 2 × 106 in 20% matrigel. Approximately two weeks after TNBC cell injection,
as tumor volume was in a range of 3-5 mm, we initiated our liposomal-miRNA treatment.
Mice were treated with either miR-484 inhibitor or control miRNA inhibitor (0.15
mg/kg≈4μg/mouse) delivered intravenously through the tail vein, once every 4 days for 4
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weeks (total of eight i.v. injections). We monitored tumor growth, by weekly
measurements of tumor volumes using an electronic caliper.

At the end of the

experimental protocol, we euthanized the mice with CO2 and determined their weight to
measure tumor growth.

Tumor tissues were dissected for further analysis by

immunohistochemistry, TUNEL (terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling), western blot, and qRT-PCR.
Preparation of miRNA nanoparticles
For in vivo targeting of miR-484, we incorporated anti-miR484 oligonucleotides into
liposomal

nanoparticles

which

were

composed

of

dimyristoyl-sn-glycero-3-

phosphocholine (DMPC) and pegylated distearoylphosphatidylethanolamine (DSPEPEG-2000) (AvantiLipids) according to our previously described protocol (161).
Immunohistochemistry
The effect of miR-484 inhibition on TNBC cell proliferation and angiogenesis in vivo was
determined by immunostaining tumor sections for Ki-67 and CD31 respectively according
to the manufacturer’s protocol. Formalin-fixed paraffin-embedded tumor tissues sections
were deparaffinized and dehydrated, then incubated in Dako (for antigen retrieval) at
95°C for 40 minutes.

Slides were then blocked with endogenous peroxidases with

methanol supplemented with hydrogen peroxide (3%) for 15 min, and then incubated with
primary antibodies for Ki-67 or CD31 overnight at a temperature of 4°C. The following
day, slides were incubated with secondary antibodies for 1 hour at room temperature.
Tumor sections were then counterstained with hematoxylin for approximately 30 seconds
and analyzed by light microscope (Nikon Eclipse TE-200-U).
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Evaluation of in vivo apoptosis (TUNEL assay)
We evaluated the effect of miR-484 inhibition on TNBC apoptosis in vivo, by measuring
the nuclear DNA fragmentation using the TUNEL assay kit (Promega) according to the
manufacturer's recommended protocol. Tumor sections from mice treated with either
control inhibitor or miR-484 inhibitor were incubated with biotin-dUTP and terminal
deoxynucleotidyl transferase for 1h. Next, we incubated tissue sections with fluorescein
conjugated avidin in the dark for half an hour, and then counterstained with Hoechst
33342 dye (Thermo Scientific) DNA. TUNEL positive cells were then determined in five
separate fields for each slide using an inverted fluorescence microscope.

Statistical analyses
Unless otherwise stated, data is expressed as means ± standard deviations (SDs) of
three independent experiments. We analyzed our data by the two tailed Student t-test to
compare significant differences between means of data sets, and p-values indicate the
probability of the means being significantly different, where *p≤0.05, **p≤0.01, ***p≤0.001,
****p ≤0.001. Data analysis was performed by Graph Pad Prism software (version 6.02)
for student t-Test and analysis of variance (ANOVA).
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miR-484 inhibition decreases cell viability & proliferation in TNBC cells
Given the observed upregulation of miR-484 in TNBC patients and cells lines, we sought
to determine the role of miR-484 in TNBC cells in vitro by various functional assays. First,
we verified successful transfection efficiency and found that miR-484 inhibitor transfected
cells (MDA-MB-231) showed significant downregulation of miR-484 levels compared to
control inhibitor transfected cells, while cells treated with miR-484 mimic had significant
upregulation of miR-484 levels compared to control mimic treated cells (Fig. 8). Next, we
examined the short-term effects of miR-484 on cell proliferation, by the MTS assay on
three different TNBC cells (MDA-MB-231, MDA-MB-436, BT-20) and normal mammary
epithelial cells (MCF-10A), treated with either miR-484 inhibitor or control inhibitor for 24,
48, and 72h. Our results showed that miR-484 inhibition significantly decreased cell
viability in TNBC cells at the indicated time points (Fig. 9, p≤0.0001), while no significant
decrease in cell viability was observed in normal mammary epithelial cells MCF-10A (Fig.
9).
Furthermore, we determined the long-term effect of miR-484 on cell proliferation by the
colony formation assay in MDA-MB-231, MDA-MB-436, and BT-20 cells. Inhibition of
miR-484 (25nM) significantly decreased colony formation in all TNBC cell lines (MDAMB-231: 41.94% ±10.07 p= 0.0099; MDA-MB-436: 44.19% ±10.66; p= 0.0119; BT-20: 50
% ± 6.193 p=0.0051) compared to cells treated with control inhibitor (Fig. 10). Moreover,
treatments of TNBC cells (MDA-MB-231 and MDA-MB-436) with miR-484 mimic
significantly increased cell viability and proliferation by the MTS assays and colony
formation assays respectively (Fig. 11 & 12), suggesting miR-484 induces cell
proliferation in TNBC cells.
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Figure 8: miR-484 inhibitor decreases the expression of miR-484 and miR-484
mimic leads to increased miR-484 expression. MDA-MB-231 cells were treated with
either miR-484 inhibitor or miR-484 mimic or control miRs (inhibitor or mimic) at 100nM for 48h.
miR-484 expression levels were analyzed by qRT-PCR and normalized to U6.
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Figure 9: Inhibition of miR-484 decreases cell viability in TNBC cells. Effects of miR484 inhibition on cell viability was assessed in MDA-MB-231, MDA-MB-436, BT-20, and MCF10A cells treated with 50nM miR-484 inhibitor or control inhibitor for 24, 48, and 72h and examined
by the MTS assay. The data are means ± SDs. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
51

Results

Figure 10: Inhibition of miR-484 decreases colony formation in TNBC cells. Effects
of miR-484 inhibition on colony formation of MDA-MB-231, MDA-MB-436, and BT-20 cells.
Colony percentage was normalized to the number of colonies formed by cells transfected with
negative control miRNA. Data is expressed as means ± SDs. *p≤0.05, **p≤0.01.
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Figure 11: Ectopic overexpression of miR-484 increases cell viability in TNBC cells.
MDA-MB-231 and MDA-MB-436 cells were treated with either miR-484 mimic or control mimic
(50nM) for 24, 48, or 72 hrs. miR-484 treatment significantly increased cell viability in TNBC cells.
Data = means ± SDs *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 12: Ectopic overexpression of miR-484 increases proliferation in TNBC
cells. miR-484 increases cell proliferation in TNBC cells. Cells were treated with miR-484 mimic
or control mimic and the number of colonies were counted after 10 days using image J software.
The data are means ± SDs. *p≤0.05, **p≤0.01, ***p≤0.001.
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miR-484 promotes cell cycle progression in TNBC cells
Deregulation of the cell cycle is often observed in many tumors, which can result in
uncontrolled cell proliferation, further promoting the process of tumorigenesis (240). The
cell cycle is composed of sequential, tightly regulated events, that drive DNA replication
and cell division (241).

Briefly, the cell cycle is divided into 4 main phases: S phase, for

DNA synthesis, M phase, in which mitosis occurs, and two gap phases G1 and G2. Some
differentiated cells may also enter a period of prolonged quiescence called G0 before
entering G1 (242). Transitions between different phases of the cell cycle is regulated by
changes in the activity of specific cyclins and cyclin dependent kinases (CDKs) (240). In
particular, the G1/S transition is a critical cell-cycle event that may be dyregulated in BC
(243). This phase is predominantly under the control of cyclin D–CDK4/6 and cyclin E–
CDK2, and can be negatively regulated by CDK inhibitors such as p21 and p27 (244).
Considering the effect of miR-484 on TNBC cell proliferation, we determined the role of
miR-484 on cell cycle progression. TNBC cells (MDA-MB-231, MDA-MB-436, and BT20) were treated with miR-484 inhibitor or control inhibitor and subjected to flow cytometry
for cell cycle analysis. Treatment of MDA-MB-231, MDA-MB-436, and BT-20 cells with
miR-484 inhibitor (100nM) significantly increased the percentage of cells in G0/G1 phases
of the cell cycle (MDA-MB-231 by 6.83%, MDA-MB-436 by 9.43%, and BT-20 by 9.61%)
and significantly decreased the percentage of cells in S phase (MDA-MB-231 by 13.71%,
MDA-MB-436 by 9.65%, and BT-20 by 18.32%) compared to cells treated with control
inhibitor miRNA (Fig. 13). Moreover, we determined the mechanism by which miR-484
regulates the cell cycle by determining the expression of G1/S phase checkpoint
regulators by Western blot analysis. Our results indicated that miR-484 inhibition reduced
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the expression Cyclin D1, Cyclin E, CDK 2, CDK4, CDK6, and induced cyclin dependent
kinase inhibitors p21 and p27 in TNBC cells (Fig. 14), further suggesting that miR-484
increases cell proliferation and cell cycle progression in TNBC.
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Figure 13: miR-484 inhibition induces G1/S phase cell cycle arrest in TNBC. Cell
cycle analysis after treatment with miR-484 inhibitor or negative control miRNA shows that miR484 inhibition increased the percentage of TNBC cells in G1 phase and decreased the percentage
of cells in S phase. Data are represented as mean ± SD of three independent experiments.
*p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.
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Figure 14: miR-484 regulates G1/S phase checkpoint mediators in TNBC. Expression
levels of CDK2, CDK4, CDK6, cyclin D1, cyclin E1, p21, and p27 were determined by Western
blot in TNBC cells (MDA-MB-231, MDA-MB-436, and BT-20) transfected with miR-484 inhibitor
or negative control miRNA. GAPDH was used as a loading control.
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Inhibition of miR-484 reduces cell motility and invasion in TNBC cells
Metastasis is the primary cause of cancer related mortality and involves dissemination of
the primary tumor to the surrounding tissues and distant organs (245). Each step of the
metastatic cascade is dependent on the motility and invasive capacity of tumor cells
including their ability to penetrate the basement membrane, escape from the primary
tumor site, migrate through the lymphatic and blood vessels, and finally intravasate or
extravasate to the distant organs (246).
Considering the significant association of miR-484 with poor OS in BC patients, we
determined the role of miR-484 on cell motility and invasion in TNBC cells by performing
in vitro wound healing and invasion assays. MDA-MB-231, MDA-MB-436, and BT-20
cells were transfected with either control inhibitor or miR-484 inhibitor (100 nM) for 48h
and subsequently wound healing assay was performed as previously described (237).
We observed that TNBC cells treated with miR-484 inhibitor showed decreased wound
healing percentage compared to control inhibitor transfected cells (MDA-MB-231
p=0.0109; MDA-MB-436 p= 0.0118, and BT-20 p=0.009) (Fig.15), suggesting that miR484 increases TNBC cell motility. Furthermore, we determined the role of miR-484 on
TNBC cell invasion using transwell invasion assay. Our results also showed that miR-484
inhibition decreased the number of invading cells compared to control miRNA-inhibitor
treatment in MDA-MB-231 (p=0.0006), MDA-MB-436 (p=0.0002), and BT-20 cells
(p=0.0019 (Fig. 16), suggesting that miR-484 expression increases the invasiveness of
TNBC cells. Moreover, overexpression of miR-484 in MDA-MB-231 and MDA-MB-436
cells with miR-484 mimic significantly increased cell motility and invasion compared to
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control cells, providing further evidence that miR-484 promotes cell motility and invasion
(Figures 17 and 18).

Regulation of cell migration and invasion in cancer cells is mediated by signaling
pathways, including SRC and focal adhesion kinase pathway (FAK) (247). The SRC
family of non-receptor protein tyrosine kinases are known to play critical roles in cell
proliferation, migration/invasion, and metastasis in many cancers including BC (248). Src
functions by mediating multiple downstream effects of receptor tyrosine kinases, such as
the EGFR family (249, 250), and its expression is reported to be elevated in many solid
tumors, including BC (251) (249). Increased Src activity can be attributed to an increase
in its transcription or to overexpression of its upstream regulators such as EGFR, HER2,
platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor
(FGFR), as well as integrins, and focal adhesion kinase (FAK) (252-254). Focal adhesion
kinase (FAK), is another critical mediator of cell adhesion and migration, which can be
recruited by intergrins to form a dual complex with Src that promotes cell motility and
survival (255).

Thus, both Src and FAK may be important therapeutics targets in

tumorigenesis (256). Figure 19 shows that miR-484 inhibition in MDA-MB-231, MDA-MB436, and BT-20 cells results in a significant reduction in both p-SRC (Tyr-416) and p-FAK
(Tyr-397) levels which is consistent with the previously described interaction between Src
and FAK in tumor cells (256).
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Figure 15: miR-484 inhibition reduces cell motility in TNBC. MDA-MB-231, MDA-MB436, and BT-20 cells were treated with miR-484 inhibitor, or negative control inhibitor (100nM), or
did not undergo transfection (NT), and cell motility was assessed by the wound healing assay.
Images are shown at 0 and 48h time points. Wound closure percentage was normalized to
untreated cells. Data is shown as means ± SDs.
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Figure 16: miR-484 inhibition reduces TNBC cell invasion. MDA-MB-231, MDA-MB436, and BT-20 cells were treated with miR-484 inhibitor or negative control inhibitor miRNA
(100nM) or not treated (NT). After 48h of transfection, cells were transferred to matrigel-coated
transwell inserts. 24h later the invaded cells were quantified and normalized to the number of
invaded cells from the NT group. Data represents means ± SDs from triplicate experiments
(***p≤0.001).
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Figure 17: miR-484 overexpression increases cell motility and invasion in TNBC.
MDA-MB-231, MDA-MB-436 cells were treated with miR-484 mimic, or negative control mimic,
and cell motility was assessed by the wound healing assay. Images were taken at 0 and 48h.
The percentage wound healing was quantified and shown on the right panel as means ± SDs
(**p≤0.01).
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Figure 18: Ectopic over-expression of miR-484 increases invasion in TNBC cells.
MDA-MB-231, MDA-MB-436 cells were transfected with miR-484 mimic or control mimic for 48h
and transferred to matrigel-coated transwell inserts and incubated for an additional 24h. The
number of invaded cells per field was quantified and shown as mean ± SDs from triplicate
experiments (***p≤0.001).
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Figure 19: miR-484 inhibition reduces p-SRC and p-FAK expression in TNBC cells.
Expression levels of p-SRC, SRC, p-FAK, FAK were determined by Western blot in TNBC cells
treated with miR-484 inhibitor (100nM) for 48h or negative control miRNA. GAPDH was used as
a loading control.
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miR-484 Inhibition induces apoptosis in TNBC cells
Given the observed effect of miR-484 inhibition on reducing cell growth in TNBC, we
subsequently investigated its role in programmed cell death. Programmed cell death I,
or apoptosis, is mainly induced by two main mechanisms: intrinsic or mitochondrial
apoptosis; and extrinsic or death receptor mediated apoptosis (257). Both pathways lead
to the activation of the caspase family of cysteine proteases, which eventually leads to
specific morphological features, typical of apoptosis, such as chromatin condensation,
DNA fragmentation, membrane blebbing, and finally complete cell lysis (258). Many
studies have shown that aberrantly expressed miRNAs are related to apoptosis evasion
in tumor progression and tumorigenesis and drug resistance (259).

MDA-MB-231, MDA-MB-436 and BT-20 cells were treated with either miR-484 inhibitor
or control inhibitor for 48h. Apoptosis following miR-484 inhibition was determined by
Annexin V/ Propidium Iodide (PI) staining, followed by flow cytometry (FACS) to
determine the percentage of apoptotic cells. The percentage of both early and late
apoptotic cells was significantly higher in TNBC cells treated with miR-484 inhibitor
compared to control cells (MDA-MB-231 p=0.0002, MDA-MB-436 p=0.0014, BT-20
p=0.0036), suggesting that miR-484 inhibition induces cell death (Fig. 20). Furthermore,
we confirmed apoptosis induction by determining the expression of apoptosis-related
proteins such as PARP, caspase-3, caspase-2, caspase-8 by Western blot (Fig. 21).
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Figure 20: Inhibition of miR-484 induces apoptosis in TNBC cells. TNBC cells were
treated with either miR-484 inhibitor or control inhibitor (100nM) for 48h, and stained by Annexin
V/PI followed by flow cytometry to determine the number of apoptotic positive cells.
Representative percentages are the sum of both early and late apoptosis. Data are represented
as means ± SD. *p≤0.05. All experiments were independently triplicated.

67

Results

Figure 21: miR-484 inhibition regulates the expression of apoptotic markers in
TNBC. Expression levels of apoptotic markers (PARP, Caspase-3, Caspase-2, Caspase-8) in
MDA-MB-231 and MDA-MB-436 cells were detected by WB after 48h transfection with miR-484
inhibitor or negative control inhibitor miRNA (100nM). GAPDH was used as a loading control.
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Aim 2:
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HOXA5 is a predicted target for miR-484
We retrieved miRNA-target interaction predictions for miR-484 from miRWalk2.0
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) that integrates results from
twelve

different

predictive

algorithms

(DIANA-microTv4.0,

DIANA-microT-CDS,

miRanda-rel2010, mirBridge, miRDB4.0, miRmap, miRNAMap, PicTar2, PITA, RNA22v2,
RNAhybrid2.1, and Targetscan6.2). We selected the 147 targets which were predicted
by at least nine algorithms (3/4 of the total number of programs checked). Among them
we chose the 16 experimentally validated targets (listed in Appendix Table 5) as retrieved
from miRWalk2.0.

Based on a literature search, we focused on HOXA5 as it was

previously shown to have a tumor suppressive role in BC (260, 261).

The predicted

binding site for miR-484 on HOXA5 3’-UTR is shown in Figure 22, and this binding site
was also found to be highly conserved among many species (Fig. 23).

Figure 22: Predicted binding site of miR-484 and HOXA5 3’-UTR.
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Figure 23: miR-484 and HOXA5 binding sites are highly conserved across many
species.
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High miR-484 expression is correlated with low HOXA5 expression in BC patients
& cell lines
The homeobox genes (HOX genes) are composed of 39 members, organized in four
clusters (A, B, C, and D), located on chromosomes 7, 17, 2, and 12, respectively (262).
HOXA5 belongs to the cluster A family of HOX regulatory genes.

The homeobox

sequence (183 nt) of HOX genes encode homeoproteins that can act as transcription
factors, to either activate or repress the expression of downstream effector target genes
(263, 264). Numerous studies during the last several decades, have highlighted the
importance of HOX genes in normal tissues, as well as in many clinical diseases and
carcinomas (265). The HOX family genes play fundamental roles in the anterior-posterior
patterning during embryonic development (266, 267). They have also been shown to be
aberrantly expressed and/or mutated in many cancers, including leukemia, colon,
prostate, breast, and ovarian cancers (268). In particular, homeobox A5 (HOXA5) has
been shown to be a key regulator of cell differentiation and organogenesis. HOXA5 has
been implicated in the development of the axial skeleton, as wells are respiratory system,
mammary glands, and digestive tracts (269). In the context of BC, HOXA5 expression
was found be reduced in more than 60% of BC cell lines, partially due to hypermethylation
of its promoter region (261). Additionally, HOXA5 has been shown to induce apoptosis,
both in a p-53 dependent or caspase 2 and 8 dependent manner in BC cells (260, 261).
Furthermore, the loss of HOXA5 expression was shown to lead to the functional activation
of Twist, a negative regulator of p53 (270), resulting dysregulation of the cell cycle and
promotion of breast carcinogenesis (271).

Collectively, these studies indicate that

HOXA5 may serve as a tumor suppressor gene in BC.
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To evaluate the potential interaction between miR-484 and HOXA5, we analyzed the
TCGA database of BC patients (n=833) and performed a spearman rank correlation
(p≤0.00001, R=0.31) and found that miR-484 was inversely correlated with HOXA5
expression in patients’ tumors (Fig. 24). Furthermore, HOXA5 protein expression was
found to be reduced in all BC cell lines (MDA-MB-231, MDA-MB-436, MDA-MB-453, BT20, MDA-MB-453, MDA-MB-361, MCF-7, and T-47) compared with normal immortalized
breast epithelial cell lines (MCF-10A and HMEC) by Western blot analysis (Fig. 25),
suggesting an inverse relationship between HOXA5 and miR-484 expression, and the
possibility that miR-484 regulates HOXA5 mRNA expression.
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Figure 24: miR-484 and HOXA5 expression levels are inversely correlated in BC
patients. Spearman correlation analysis showed a negative and significant correlation between
miR-484 and its target gene HOXA5 in BC patients (n=833). R=0.31, p≤0.0001.
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Figure 25: miR-484 and HOXA5 expression levels are inversely correlated in BC cell
lines. A) HOXA5 expression levels are lower in BC cell lines compared to normal breast epithelial
cells MCF-10A and HMEC. Basal HOXA5 expression levels were analyzed by WB and GAPDH
was used as loading control. B) miR-484 basal expression levels were assessed by qRT-PCR.
U6 was used as internal control. C) Pearson correlation analysis showing a negative and
significant correlation between miR-484 and HOXA5 in BC cells. R=0.8, p=0.041.
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miR-484 directly binds to the 3’-UTR of HOXA5 to regulate its expression
miRNAs are involved in post-transcriptional regulation of gene expression mainly by
directly binding of the 3’-UTR of their target mRNAs to negatively regulate their
expression (72).

To evaluate the effect of miR-484 on HOXA5 gene and protein

expression in TNBC cells, we transfected MDA-MB-231, MDA-MB-436, and BT-20 cells
with miR-484 inhibitor (100nM) or negative control inhibitor for 48h. Inhibition of miR-484
resulted in significant reduction in HOXA5 protein and mRNA expression in the cell lines
detected by Western blot and qRT-PCR analysis, respectively (Figures 26 and 27).
Collectively, these results suggests that miR-484 suppresses HOXA5 protein and mRNA
expression levels in TNBC cells.
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Figure 26: miR-484 reduces HOXA5 protein expression levels in TNBC cells.
MDA-MB-231, MDA-MB-436, and BT-20 cells were treated with miR-484 mimic or control mimic
(100nM) for 48h and cell lysates were analyzed for HOXA5 expression by WB analysis. GAPDH
was used as loading control.
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Figure 27: miR-484 reduces HOXA5 mRNA expression levels in TNBC cells. Cell
lines were analyzed for HOXA5 mRNA levels by qRT-PCR 48h after miR-484 transfection. Data
is represented as fold change normalized to GAPDH expression levels. *p≤0.05.
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miR-484 directly binds to HOXA5 3’-UTR to negatively regulate its expression
To further prove the direct role of miR-484 on HOXA5 mRNA regulation we identified the
consensus sequences on the 3-UTR region of the HOXA5 gene for binding to miR-484
and performed a luciferase gene reporter assay. The human wild type (WT) HOXA5 3’UTR was cloned upstream of a firefly luciferase gene in a reporter vector (pEZX-MT06)
plasmid. A similar vector containing the mutated sequence (GAGCCTG> GCTACAG) in
the miR-484 binding site of the HOXA5 3’-UTR-mut (pMSCV–HOXA5-3’-UTR-mut) was
used as a negative control. The resulting plasmids were separately transfected into MDAMB-231 and MDA-MB-436 cells along with miR-484 mimic or negative control miRNA
(100nM). Firefly luciferase activity was measured and normalized to Renilla Luciferase
activity. As shown in Figure 28, cells treated with miR-484 and expressing the WT 3’UTR of HOXA5 had significant reduction in luciferase activity compared to cells treated
with control miRNA (MDA-MB-231 p=0.0021 and MDA-MB-436 p≤0.0001). Moreover,
cells expressing the pEZX-MT06 miRNA reporter vector containing the mutated miR-484
binding site (pMSCV–HOXA5-3’-UTR-mut) showed no significant difference in luciferase
activity between miR-484 and control miRNA transfections. Thus, our findings suggest
that miR-484 binds specifically to the WT HOXA5 3’-UTR to negatively regulate its mRNA
expression.
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Figure 28: miR-484 directly binds to HOXA5 3’-UTR in TNBC cells. Luciferase reporter
assay showing that miR-484 directly binds to the 3’-UTR of HOXA5 luciferase reporter in MDAMB-231 and MDA-MB-436 cells. Firefly luciferase activity was normalized to endogenous Renilla
luciferase activity. Data are represented means ± SDs for three independent experiments.
*p≤0.05
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miR-484 mediates its effects through inhibition of HOXA5 tumor suppressor in
TNBC cells
Reduced cell proliferation in cancer is often associated with concomitant activation of cell
death pathways and inhibition of cell cycle progression (272). We have shown that miR484 inhibition significantly induces apoptosis and promotes G1/S cell cycle arrest in TNBC
cells. Furthermore, HOXA5 expression has been shown to lead to activation of cell death
pathways (260, 261) and aberrant cell cycle regulation (271). Therefore, we examined
the role of HOXA5 in mediating apoptosis in response to miR-484 inhibition. First, we
transduced MDA-MB-231 cells with HOXA5-expressing lenti-based vector and control
empty-vector that lack HOXA5 gene. Light microscopy revealed that HOXA5
overexpressing cells displayed typical apoptotic morphology such as cell shrinkage and
appeared denser compared to controls (273) (Fig. 29).

Furthermore, HOXA5

overexpressing cells showed increased apoptosis by FACS, which was reversed by
expression of miR-484 mimic (Fig. 30). This finding was also associated with a reduction
in HOXA5 expression levels (Fig. 31). Moreover, HOXA5 overexpression recapitulated
the effects of miR-484 inhibition on apoptotic markers such as PARP and capase-3 and
G1/S cell cycle regulators such as Cyclin D1, Cyclin E1, CDK4, and

induced the

expression of CDK inhibitors p21 and p27 (Fig. 32). Overall, our findings suggest that
miR-484 could promote TNBC cell survival through downregulation of HOXA5 tumor
suppressor gene.
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Figure 29: HOXA5 overexpressing cells display typical apoptosis morphological
features. MDA-MB-231 cells were transduced with lentiviral expression vector incorporating
WT-HOXA5 (NM_019102.3) (HOXA5-OE) for overexpression of HOXA5 or the mock empty
vector (EV) (LPP-NEG-Lv103) and examined under the light microscope 48h after transduction.
HOXA5 overexpressing cells appeared smaller and denser compared to cells expressing control
empty vector. Magnification 4X.
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Figure 30: miR-484 reverses HOXA5 induced apoptosis. MDA-MB-231 cells overexpressing either HOXA5 or mock empty vector were co-transfected with either miR-484 mimic
or control mimic (100nM) and collected after 48h. Cells were stained with Annexin/PI for FACS
analysis of the apoptotic positive cells. Data are represented as mean ± SD. **p≤0.01. All
experiments were independently triplicated.
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Figure 31: miR-484 partially reduces HOXA5 expression in HOXA5 overexpressing
cells. MDA-MB-231 cells overexpressing HOXA5 (HOXA5-OE) or expressing control empty
vector (EV) were treated with either miR-484 mimic or control mimic (100nM) and collected after
48h. Cell lysates were analyzed for HOXA5 expression levels by Western blot. GAPDH was
used an internal control.
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Figure 32: HOXA5 overexpression recapitulates miR-484 inhibition on apoptosis
and cell cycle markers. MDA-MB-231 cells overexpressing HOXA5 lentiviral vector (HOXA5OE) or expressing control empty vector (EV) were treated with either miR-484 mimic or control
mimic (100nM) and collected after 48h. The levels of HOXA5, PARP, caspase-3, Cyclin D1,
Cyclin E1, p27, and p21 were determined by WB. GAPDH was used as loading control.
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miR-484 alters multiple proteins/cancer signaling pathways in TNBC:
To determine the potential signaling pathways that are regulated by miR-484 in TNBC,
we performed a reverse phase protein array (RPPA) analysis of MDA-MB-231 cells
treated with either miR-484 mimic or control miRNA. Samples were probed with 304
proteins, including total and phospho-proteins. Among the proteins that were probed for,
we found a total of 55 proteins that were significantly upregulated with miR-484
overexpression compared to controls, and a total of 61 proteins that were significantly
downregulated with miR-484 treatment compared to controls.

Significantly altered

proteins after miR-484 transfection are shown in the heat map in Figure 33. Of particular
interest to us, we observed significant downregulation of caspase-8 (FCH=-1.09 pvalue=0.11), p53 (FCH=-1.074 p-value=0.014), Bax (FCH=-1.04 p-value=0.031) with
miR-484 overexpression, and significant upregulation of cyclin D1 (FCH=+1.18 pvalue=0.012) with miR-484 treatment. Furthermore, our ingenuity pathway analysis
showed that miR-484 overexpression in MDA-MB-231 cells resulted in alteration in many
signaling pathways related to cell proliferation, apoptosis, and cell cycle regulation (Fig.
34), which is consistent with our previously mentioned findings. Figure 35 summarizes
the findings from our IPA analysis and illustrates the interaction between miR-484 and
HOXA5 in regulating certain apoptosis related proteins such as PARP and caspases as
well as cell cycle regulators such as cyclins and CDKs.
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Figure 33: Overexpression of miR-484 significantly alters multiple proteins
involved in cancer signaling in TNBC. Heat map of RPPA analysis showing significantly
altered proteins after miR-484 transfection in MDA-MB-231 cells. Green color indicates that
expression levels were reduced with miR-484 treatment compared to control miRNA treatment,
while red color indicates that the expression levels were increased with miR-484 transfection
compared to controls.
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Figure 34: miR-484 overexpression significantly alters multiple cancer signaling
pathways in TNBC. The pathway annotations obtained by Ingenuity Pathway Analysis (IPA)
show that ectopic overexpression of miR-484 in MDA-MB-231 cells led to alteration in multiple
canonical pathways related to cancer.
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Figure 35: Ectopic overexpression of miR-484 regulates HOXA5 and multiple
downstream targets in TNBC. Ingenuity Pathway Analysis (IPA) showing the canonical
pathways/proteins that were significantly downregulated (green) or upregulated (red) by miR-484
in TNBC cells. Graphs produced by RPPA analysis of MDA-MB-231 treated with miR-484 or
control mimic for 72h.
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Aim 3:
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In vivo therapeutic targeting of miR-484 suppresses growth of orthotopic TNBC
xenograft tumors and induces HOXA5 expression
We have shown that miR-484 is upregulated in TNBC cell lines and is associated with
poor patient survival and prognosis. Therefore, to demonstrate the in vivo effects of miR484 in promoting TNBC tumorigenesis and progression as well as the therapeutic
potential of targeting this oncogenic miRNA, we inhibited miR-484 in orthotopic MDA-MB231 and MDA-MB-436 TNBC mouse models. Tumor cells (2 X 106 cells/mouse) were
orthotopicaly injected in into the mammary fat pad of female nude athymic mice (n=5).
After approximately one week, we injected dimyristoyl-sn-glycero-3-phosphocholinebased liposomal nanoparticles (237) incorporating anti-miR-484 (0.15 mg/kg, i.v.) once a
week, for 4 weeks. At the end of the treatment we evaluated the in vivo effects of miR484 downregulation on tumor growth and analyzed for proliferation, angiogenesis, and
apoptosis by IHC. Mice treated with miR-484 inhibitor showed decreased expression of
miR-484 levels in tumors (Fig. 36) compared to control inhibitor, and had a significant
decrease in tumor volume compared to control mice (Fig. 37) (p≤0.05).
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Figure 36: Systemic delivery of Anti-miR-484 reduces miR-484 expression levels in
orthotopic xenograft TNBC mouse models. MDA-MB-231 and MDA-MB-436 cells were
orthotopically injected in female nude athymic mice (n=5). Mice were then treated with either
control inhibitor or miR-484 inhibitor liposomal nano-particles delivered I.V. once every 4 days, for
4 weeks. miR-484 expression levels were analyzed from tumor samples by qRT-PCR. U6 was
used as internal control.

92

Results

M D A -M B -2 3 1

C T L I n h ib it o r

2500

*

)

m iR - 4 8 4 I n h ib it o r

T u m o r s iz e (m m

3

2000

**
1500

1000

500

0

1

2

3

4

W eeks

M D A -M B -4 3 6

C T L I n h ib it o r

300
m iR - 4 8 4 I n h ib it o r

T u m o r s iz e (m m

3

)

**

200

100

4

3

2

1

0

W eeks

Figure 37: In vivo systemic delivery of Anti-miR-484 nanoparticles decreases
tumor volume in TNBC mouse xenografts. Tumor volumes were determined once a week
for 4 weeks and data is represented as means ± SD. *p=≤0.05.
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To assess the effects of miR-484 inhibition on cell proliferation, angiogenesis, and
apoptosis, tissue sections were stained with hematoxylin and eosin followed by
immunohistochemical analysis for Ki-67 expression as a proliferation marker, and CD31
as a marker for angiogenesis. Additionally, we analyzed the effects of miR-484 inhibition
on apoptosis by the Terminal deoxynucleotidyl transferase–mediated dUTP nick end
labeling (TUNEL) assay which detects nuclear DNA fragmentation in apoptotic cells. Our
results showed that mice treated with miR-484 inhibitor had a greater reduction of Ki-67–
positive tumor cells compared to mice treated with control inhibitor (MDA-MB-231
p=0.0011, MDA-MB-436 p=0.0093) (Fig. 38).

Furthermore, miR-484 inhibition

dramatically decreased micro-vessel density, as represented by CD31-positive cells,
compared to control inhibitor miRNA (Fig. 39) in both orthotopic tumor models (MDA-MB231 p=0.024, MDA-MB-436 p=0.0192), suggesting that inhibition of miR-484 has an
antiangiogenic effect in TNBC mouse models. Additionally, miR-484 inhibition
significantly increased the number of TUNEL-positive cells compared to control inhibitor
miRNA (Fig. 40) (MDA-MB-231 p=0.0019, MDA-MB-436 p=0.0049), suggesting that miR484 inhibition has a pro-apoptotic effect in vivo. Overall, our findings indicate that miR484 inhibition decreased tumor growth in orthotopic TNBC mouse models through
significant suppression of cell proliferation and angiogenesis and induction of apoptosis.
Furthermore, we assessed the HOXA5 expression levels by both WB and PCR and
observed that miR-484 inhibition significantly increased HOXA5 protein and mRNA
expression levels by Western blot (Fig. 41) and qRT-PCR analysis (Fig. 42) respectively
in both tumor models, providing further evidence that miR-484 pro-tumorigenic effect in
TNBC mouse models is mediated by suppression of HOXA5 in TNBC.
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Figure 38: miR-484 inhibition decreases Ki-67 expression. Tumor cell proliferation was
analyzed by determining Ki-67 expression in tumor tissues by immunohistochemistry.
Magnification X20.
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Figure 39: miR-484 inhibition decreases CD31 expression. Tumor tissue sections were
analyzed for CD31 expression as a micro-vessel density marker by immunohistochemistry.
Magnification X20.
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Figure 41: miR-484 inhibition increases HOXA5 protein expression levels in TNBC
orthotopic xenografts. TNBC tumor cell lysates were analyzed for HOXA5 expression levels
by Western blot analysis. GAPDH was used as a loading control.
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Figure 42: miR-484 inhibition increases HOXA5 mRNA expression levels in TNBC
orthotopic xenografts. RNA was isolated from TNBC tumor samples and analyzed for miR484 expression by qRT-PCR. miR-484 inhibition increase HOXA5 mRNA expression levels in
TNBC xenograft tumors. Data is represented as fold change normalized to GAPDH as
endogenous control.
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DISCUSSION:
Triple negative breast cancer is a very heterogenous and aggressive BC subtype, that
lacks specific markers (i.e. ER, PR and HER2) for effective targeted therapy (eg. antiestrogens, anti-HER2 therapies) (6, 49). Currently, TNBC has six different genetically
defined subtypes, making it highly difficult to identify common molecular targets for
development of targeted therapies (7). Several gene expression and miRNA profiling
studies have been carried out in order to identify particular miRNA signatures in TNBC
patients (274). Moreover, several miRNAs have been identified to play a crucial role in
TNBC carcinogenesis, providing a basis for their possible therapeutic application with
promising results (274). Thus, the application of miRNA based therapy represents an
innovative approach, especially for TNBC patients with limited therapeutic options.
The key findings in our study is that miR-484 is a clinically significant oncogenic miRNA
that is highly expressed in TNBC patients and is associated with poor OS and prognosis.
Additionally, we found that miR-484 acts as an onco-miR by directly binding and
regulating the expression of the tumor suppressor gene HOXA5 in TNBC. Our study also
provides the first evidence that in vivo therapeutic targeting of miR-484 by systemically
injected anti-miR-484 nanoparticles significantly inhibits tumor growth and induces
HOXA5 expression in TNBC tumor models.
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Significance of miR-484 in Cancer
Certain miRNAs have been shown to behave either as oncogenic or as tumor suppressor
miRNAs depending on the cellular context (103). Such is the case for miR-484, as it has
been reported to either act as a tumor suppressor or oncogenic miRNA depending on the
cancer type.
The potential oncogenic role of miR-484 has been previously reported in renal cell
carcinoma (RCC), where miR-484 was shown to correlate with drug resistance to
Sunitinib (tyrosine kinase inhibitor) (275, 276). Patients expressing high miR-484 levels
had a median time to progression (TTP) of 5.8 months, whereas patients with low miR484 expression had a median TPP of 8.9 months. Although the exact mechanism of
action of miR-484 in RCC is not yet elucidated, this study suggests that miR-484 may be
utilized as a potential predictive biomarker in RCC patients treated with Sunitinib.
Additionally, Wang and colleagues showed that miR-484 targets mitochondrial fission
protein Fis1, which is induced by anoxia; thereby inhibiting mitochondrial fission and
apoptosis in cardiomyocytes and in adrenocortical cancer cells (277). Furthermore, they
showed that the transcription factor Foxo3a activated miR-484 expression by binding to
its promoter region, and that this binding was attenuated by anoxia (277). Other studies
have also suggested the clinical significance of miR-484 as a diagnostic biomarker in
cancer. For example, miR-484 was found to be a predictive biomarker for prostate cancer
recurrence (278). Another study reported that miR-484 is a predictive biomarker that is
highly

expressed

in

metastatic

CRC

patients

treated

with

combination

5-

flurouracil/oxaliplatin (279). However, to our knowledge the mechanism of action of miR484 in prostate or colon cancer has not been defined as of yet.
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On the other hand, miR-484 was reported to act as a tumor suppressor miRNA in cervical
cancer, leading to suppression of proliferation, migration/invasion, and induction of
apoptosis in vitro. Mechanistically, ZEB1 and SMAD2 were identified as miR-484 targets
using predictive algorithms and miR-484 was shown to reduce their expression levels,
while overexpression of ZEB1 and SMAD2 reversed the events mediated by miR-484 in
cervical cancer cells (280). miR-484 was also reported to be among three miRNAs
implicated in classifying ovarian cancer patient response to chemotherapy (281).
Moreover, miR-484 was found to modulate the tumor vasuclature by targeting VEGF-B in
tumor cells and VEGF-R2 in adjacent endothelial cells (281).

Clinical and Functional Significance of miR-484 in Breast Cancer
Here we report for the first time that miR-484 is highly expressed in TNBC subtype of BC
patients compared to non-TNBC and normal subtypes. Moreover, we found that high
miR-484 expression is correlated with worse OS and prognosis in BC patients. In support
of our findings, a previous study found that miRNA-484 is differentially expressed in
different clinical and molecular subclasses of invasive BC (234). Utilizing genome-wide
data for miRNA/mRNA expression and DNA methylation, an integrated survival analysis
was performed on 466 BC patients.

This analysis revealed a distinct prognostic

signature, composed of seven miRNAs, including miR-484, and 30 mRNA genes, and
was successfully validated on eight other BC cohorts (234).

Furthermore, Zearo and

colleagues reported that miR-484 is significantly upregulated in the serum of early BC
patients, suggesting its potential as an early diagnostic biomarker in BC (235). Thus, our
data, complemented by the previous findings highlight the clinical significance of miR-484
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as a biomarker in BC, and further demonstrated the significance of miR-484 expression
in TNBC.
To our knowledge, we are the first to report the functional role of miR-484 in TNBC. Our
in vitro functional assays showed that miR-484 inhibition significantly reduced TNBC cell
viability, cell proliferation, motility/migration, while inducing G1/S cell cycle arrest, and
apoptosis. Moreover, opposite effects were observed by the treatment of cells with miR484 mimic, providing further evidence for the oncogenic role of miR-484 in TNBC. In
support of our findings, Ye and colleagues recently showed that miR-484 is implicated in
cell proliferation and cell cycle regulation.

In their study, miR-484 overexpression

promoted cell proliferation and cell cycle progression by targeting cytidine deaminase
enzyme in gemcitabine resistant BC cells (282). We also utilized RPPA as an unbiased
platform to provide us with the proteomic analysis in order to understand the potential role
of miR-484 in vitro after its overexpression in TNBC cells (239). The comprehensive
analysis of the RPPA data unraveled the link between miR-484 and signaling pathways
involved in apoptosis and cell cycle progression, which we further confirmed by western
blot analysis.

Deregulated Expression of Tumor Suppressor HOXA5 by Onco-miR-484 in Breast
Cancer

HOX genes are defined by a DNA-binding domain called the homeodomain which
encodes for transcription factors that can function to either upregulate or repress the
transcription of downstream targets. Numerous studies over the past several decades
have demonstrated that HOX genes play a crucial role in the normal temporo-spatial limb
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(283) and organ (284-286) development along the anterior-posterior (A-P) axis (287).
Additionally, several studies have also revealed that HOX genes can be aberrantly
expressed or mutated in many cancers, acting to either promote or suppress tumor
development (288, 289), by regulating processes such as cell proliferation, angiogenesis,
apoptosis, and tumor metastasis (290-293). This aberration could be mainly attributed to
three main mechanisms: 1) temporospatial deregulation, where HOX gene expression in
tumors is temporospatially different than in normal tissues; 2) gene dominance, where
HOX genes are expressed at higher levels in cancer tissues versus normal; and 3)
epigenetic deregulation in which HOX genes are either downregulated or silenced in
tumors (288).

HOXA5 is a member of the cluster A family of HOX genes located on chromosome.
7p15.2 (289). HOXA5 has been shown to be a key regulator of cell differentiation and
organogenesis particularly in the axial skeleton, respiratory system, mammary glands,
and digestive tracts (269). HOXA5 has also been shown to regulate many processes in
carcinogenesis namely in breast, lung, colon, ovarian, and hematological malignancies
(269).

Previous literature suggest that HOXA5 may function as a tumor suppressor in BC.
HOXA5 expression has been shown to be decreased in almost 60% of BC cell lines,
which is partially attributed to hypermethylation of the HOXA5 promoter region (261).
Moreover, reduced HOXA5 expression was found to be correlated with progression to
higher-grade BC stages (261, 294), further supporting our findings of the association of
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low HOXA5 with poor OS in BC patients. In the context of BC, HOXA5 has been shown
to have a growth suppressive effect by promoting apoptosis in a p53-dependant or
independent manner. Raman and colleagues showed that HOXA5 interacts with the p53
promoter to activate it expression and thus induce p53-mediated apoptosis in MCF-7 ER+
BC cells (261). Additionally, HOXA5 was shown to bind with TWIST (a negative regulator
of p53), thereby reducing its suppressive effect on p53 in BC cells (271). Alternatively,
HOXA5 was also shown to induce apoptosis in a p53-independent independent way via
caspases 2 and 8 (260).
Other studies have also shown that HOXA5 is involved in retinoic acid (RA) induced
apoptosis in BC cells, where RA was shown to induce HOXA5 expression to mediate its
growth suppressive effects.

Furthermore, a follow up study revealed a post-

transcriptional modulation of RA-induced HOXA5 expression, where miR-130a and the
RNA binding protein-human antigen R were found to be involved in HOXA5 upregulation
following RA treatment (295).

Furthermore, Teo and colleagues defined the role of HOXA5 in maintaining certain
molecular features such as cell-cell adhesion and markers of differentiation in mammary
epithelial cells. In their study, reduced HOXA5 expression was shown to increases the
self-renewal capacity and the acquisition of a more aggressive phenotype in mammary
epithelial cells, via a reduction in E-cadherin and CD24 levels, whereas HOXA5
overexpression promoted the differentiation of the progenitor population to a more
differentiated state (296).
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Utilizing our miRNA target prediction strategy, we identified HOXA5 as a target for miR484, and demonstrated that miR-484 directly binds to the HOXA5 3’-UTR to negatively
regulate its expression. Furthermore, we showed that miR-484 is inversely correlated
with HOXA5 expression in BC patients and cell lines, suggesting that high expression of
miR-484 in BC patients, particularly in TNBC patients, may be one of the major causes
that contribute to the suppression of HOXA5 tumor suppressor gene. In agreement with
previously published data (260, 261), we found that HOXA5 over expression promoted
cell death through apoptosis, which was associated with an increase in the active forms
of caspase-2 and capsase-8. Furthermore, the growth inhibiting effects of HOXA5 were
reversed with ectopic overexpression of miR-484 in TNBC cells. Moreover, we also
showed that HOXA5 overexpression recapitulated the effects of miR-484 inhibition on cell
cycle progression, whereby we observed the inhibition of cell cycle proteins including
cyclin D1, cyclin E1, as well as CDK4 which is being targeted by novel inhibitors in the
clinical trials (297). Since p53 is mutated in almost 80% of TNBC patients (298) and the
TNBC cell lines used in our study (MDA-MB-231, MDA-MB-436, and BT-20) harbor p53
mutations (299), it is possible that HOX5 mediated effects may mostly be mediated
through p53 independent mechanisms.

Aberrant HOXA5 and miR-484 levels were also reported in other cancer types besides
BC, suggesting the existence of a possible regulatory pathway in other tumors. For
instance, HOXA5 expression levels were found to be reduced in non-small cell lung
cancer (NSCLC) patients, where HOXA5 was shown to induce cell proliferation by
upregulating Cdkn1a, encoding the cyclin-dependent kinase inhibitor p21 (300-302).
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Interestingly, miR-484 was shown to promote NSCLC oncogenesis through inhibiting
apoptotic protease activating factor (Apaf-1) associated with the suppression of apoptosis
(303). However, whether miR-484 function in NSCLC is also via targeting HOXA5 levels
would be a point of further investigation.

miR-484 was also reported to be highly expressed in serum of colorectal cancer (CRC)
patients, with its highest expression in the later stages (III-IV) (279, 304), suggesting that
it may function as an oncogenic miRNA in CRC. On the contrary, HOXA5 levels were
shown to be downregulated in CRC tumors, which was associated with upregulation of
the Wnt/β-catenin pathway. Moreover, HOXA5 overexpression in CRC lead to reduction
of their self-renewal capacity via inhibition of Wnt signaling, along with reduction in tumor
size and metastasis (305).

HOXA5 expression was also found to be lost in angiogenic endothelial cells of the tumor
vasculature, suggesting the role of HOXA5 in suppressing tumor angiogenesis. Previous
studies reported that HOXA5 overexpression was found to inhibit the expression of proangiogenic factors such as VEGFR2, while inducing the anti-angiogenic factor
Thrombospondin-2 (TSP-2) (306). Additionally, restoring the expression of HOXA5 also
inhibited angiogenesis in brain hemangiomas in mice, which was associated with
increased TSP-2 and reduced hypoxia inducible factor 1 (HIF-1α) expression levels (307).
In our study, our RPPA analysis revealed that miR-484 induces HIF-1α expression in
TNBC, one of the major drivers of oncogenesis. Additionally, we found that in vivo
inhibition of miR-484 reduced angiogenesis in TNBC tumor xenografts, which was
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associated with an increase in HOXA5 expression levels.

Collectively, these data

suggest that miR-484 may promote angiogenesis in TNBC, and the possible existence of
a regulatory pathway between miR-484 and HOXA5/HIF-1α in modulating angiogenesis
in TNBC, could be a point of further exploration.

miR-484 as a Novel Molecular Target in TNBC

Since numerous studies have demonstrated that miRNAs are aberrantly expressed in
many cancers, and have the ability to regulate multiple cancer-related genes and
pathways simultaneously, the use of miRNA based therapies represents a promising
therapeutic approach against cancer (308). Indeed several miRNAs are currently in
clinical development or are being evaluated in clinical trials as a therapeutic modality
against cancer (203).

One of the key findings in our study is that in vivo therapeutic targeting of miR-484 by
systemically injected anti-miR-484 nanoparticles significantly inhibits tumor growth in
TNBC tumor models, with no sign of toxicity during 4 weeks of treatment. Considering
the clinical significance and broad expression of miR-484 in TNBC cell lines and BC
patients (non-TNBC and TNBC tumors), miR-484 represents an excellent molecular
target in BC especially in the TNBC subtype.

A major obstacle in the field of miRNA-based cancer therapy is developing a safe and
effective systemic delivery of therapeutic miRNAs in vivo. Some obstacles that hinder
successful miRNA delivery in vivo include degradation by enzymatic nucleases, as well
as poor cellular uptake, and poor stability (309).
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Thus, the ideal delivery system for miRNAs or miRNA antagomirs should provide
sufficient target binding that is tumor tissue specific, and be packaged in a carrier that is
biodegradable and non-immunogenic (225). One such strategy that has been extensively
investigated in the field of RNA interference is the use of nanocarriers. Nanoparticles are
submicron in size, usually made up of natural or synthetic lipids or polymers, that can be
utilized to deliver various cargos such as drugs and oligonucleotides in vivo (230).
Nanoparticles also offer the advantage that they can be coated with high-affinity ligands
for tumor-specific receptors to achieve controlled and/or sustained delivery (308).

Liposomal nanoparticles are among the favorable options for systemic miRNA delivery in
vivo. (230).

Advantages of these nanoliposomes include their biocompatible and

biodegradable characteristics, and lack of any apparent toxicity (230). Several studies
have shown that incorporation of miRNA mimics/inhibitors in neutral nanoliposomes
achieved significant reduction in tumor volume and altered the expression of target genes
in many cancer models including subcutaneous xenografts and orthotopic tumor models
(161, 237, 310). Moreover, neutral nanoliposomes did not cause any detectable distress
or toxicity and were found to be safe in mice (161).

In our study, we provide the first evidence that in vivo therapeutic targeting of miR-484 by
nanoliposomes made of DMPC successfully delivered anti-sense miR-484 and reduced
miR-484 expression in orthotopic TNBC mouse models as detected by qRT-PCR.
Furthermore, mice treated with miR-484 inhibitor showed an increased expression of
HOXA5, as well as reduced intra-tumoral proliferation and angiogenesis, and induction of
apoptosis. Additionally, we observed a significant inhibition in tumor growth in the miR-
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484 targeted group compared to controls, with no observed side effects, suggesting that
miR-484 could be a potential therapeutic target in TNBC. Mechanistically, given the
previously described role of HOXA5 in inducing apoptosis in BC cells in vitro (260, 261),
as well as it anti-angiogenic effect on endothelial cells (306, 311), the observed miR-484
effects in vivo may be in part via induction of HOXA5 expression.

In conclusion, our study provides new insight into the role and mechanism of action of
miR-484 in TNBC as a potential molecular target, which can further be utilized to develop
safe and effective miRNA-based therapies for TNBC patients with limited therapeutic
options. Collectively, our in vitro and in vivo data, as well as the protein array results
suggest that miR-484 promotes tumor growth, invasion, metastasis, and progression in
TNBC cells by regulating multiple oncogenic pathways. The key findings for our three
specific aims are summarized in Figure 43. Thus, our data suggest that miR-484 may
function as an “onco-miR” in TNBC and may therefore serve a potential therapeutic target.
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Figure 43: Summary of the key findings depicting the role and mechanism of action
of miR-484 in TNBC.
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Evaluating the role of miR-484 and HOXA5 in other breast cancer subtypes:
One of the critical findings in our study is that miR-484 is significantly associated with
poor OS in BC patients. According to our TCGA analysis we also found that miR-484 is
upregulated in all BC subtypes compared to matched normal tissues, with the highest
expression in the TNBC subtype. Furthermore, we showed that HOXA5 and miR-484
expression levels are inversely correlated in BC patients and cell lines, suggesting that
miR-484 may also promote tumor growth and progression in other BC subtypes by
targeting HOXA5. Therefore, further evaluation of role of miR-484 in other BC tumors
and whether it functions by targeting HOXA5 may be investigated.

Determining the mechanism of aberrant miR-484 expression in Breast Cancer:
Aberrant miRNA expression could be due to genetic, epigenetic factors, or factors that
affect miRNA biogenesis/processing (312). However, the causes for dysregulation of
miR-484 expression in TNBC are currently not known. miRNA transcription can be
activated by transcription factors that bind to its promoter region. In search for possible
transcription factors on the miR-484 promoter region (biobase.mdanderson.edu), we
found that Nuclear Factor Kappa-B (NF-kB) (Rel A p65 subunit) has multiple predicted
binding sites on the miR-484 promoter region (data not shown). NF-kB is a transcription
factor that is involved in almost all aspects of human cancer (313, 314), and represents
a key regulator of TNBC (315, 316). Moreover, NF-kB has been implicated in the
dysregulated expression of many miRNAs (317). Thus, further confirmation by CHIP
assay of whether NF-kB directly binds to the miR-484 promoter to regulate its expression
could be investigated.
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Further confirmation that miR-484 mediated events in TNBC are through down
regulation of HOXA5:

In this study we showed that inhibition of miR-484 in TNBC cells significantly reduced cell
proliferation, motility/invasion, and induced cell cycle arrest and apoptosis. On the other
hand, miR-484 overexpression resulted in increased cell proliferation, survival, motility
and invasion, suggesting that it functions as an oncogenic miRNA in TNBC. Furthermore,
we identified HOXA5 as a direct target of miR-484 and found that miR-484 directly binds
to the 3’-UTR of HOXA5 to negatively regulate its expression. Additionally, HOXA5 overexpression recapitulated the effects of miR-484 inhibition on apoptosis induction, while
miR-484 overexpression reversed this effect, suggesting that miR-484 mediates its
effects through HOXA5 suppression. However, further examination of whether miR-484
effects on cell proliferation, motility, and invasion are through HOXA5 downregulation
should be considered. Thus, determining whether siRNA mediated knockdown of HOXA5
can recapitulate miR-484 effects in TNBC could be examined.

Analysis for in vivo toxicity of Anti-miR-484 treatment in TNBC mouse models:

In our study, no significant changes in mouse body weights, nor changes in behavioral or
eating habits were detected during the 4 weeks of the treatment of mice, suggesting that
anti-miR-484 therapy exerted no or limited side effects. However, further confirmation by
clinical biochemistry analyses for mice treated with either miR-484 inhibitor or control
inhibitor nanoliposomes should be compared. This can include biochemical parameters
for kidney, liver, and blood toxicity such as, blood urea nitrogen, glucose, aspartate
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aminotransferase, alanine aminotransferase, creatinine, total bilirubin, and lactic
dehydrogenase.

Further confirmation of miR-484 oncogenic effects in TNBC mouse models:
We showed that treatment with miR-484 inhibitor reduced tumor growth, proliferation, and
angiogenesis, and induced apoptosis in TNBC mouse models. Moreover, we observed
that these effects were associated with increased HOXA5 expression levels. However,
further confirmation of the oncogenic effects of miR-484 can be explored by injecting mice
with miR-484 mimic to determine its effects on proliferation, angiogenesis, and apoptosis
would be warranted. Additionally, tumor samples from mice treated with either miR-484
inhibitor or mimic can be evaluated for the proliferation, angiogenesis, and apoptosis
markers by western blot.

Determining the effect of miR-484 inhibition in combination with standard
chemotherapy in TNBC:

According to our in vitro and in vivo results, miR-484 promotes tumor growth and
progression in TNBC and therefore represents a potentially novel therapeutic target.
However,

further

evaluation

of

combining

miR-484

inhibitors

with

standard

chemotherapeutics could be evaluated in order to determine a possible synergistic effect
and maximize treatment efficacy.

Our preliminary experiments have shown that

combination of miR-484 inhibitor with standard chemotherapeutics such as paclitaxel or
doxorubicin significantly reduced TNBC cell proliferation than either mono therapies (data
not shown). Therefore, further investigation of whether miR-484 increases doxorubicin
or paclitaxel sensitivity in TNBC cells may be explored.
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Table 3: Antibodies used in Western Blot analysis
Target Protein

Catalog
Number

Source

Application

GAPDH

Cell Signaling Technology

5174

WB, IHC, IF

HOXA5

Santa Cruz

365784

WB, IP, IF

Caspase-2

Cell Signaling Technology

2224

WB

Caspase-8

Cell Signaling Technology

9746

WB, IP

Cleaved
Caspase-8

Cell Signaling Technology

9496

WB, IHC, IF

Caspase-3

Cell Signaling Technology

9662

WB, IHC, IP

PARP

Cell Signaling Technology

9532

WB, IP, IF

p-FAK (pY397)

B&D Biosciences

611722

WB

FAK

B&D Biosciences

610087

WB

p-SRC (Tyr416)

Cell Signaling Technology

2101

WB

SRC

Cell Signaling Technology

2109

WB, IHC, IF, IP

CDK2

Cell Signaling Technology

2546

WB, IP

CDK4

Cell Signaling Technology

12790

WB, IHC, IF

CDK6

Cell Signaling Technology

13331

WB, IP

Cyclin D1

Cell Signaling Technology

2978

WB, IHC

Cyclin E1

Cell Signaling Technology

20808

WB

p21

Cell Signaling Technology

2947

WB, IHC, IP, IF

p27

Cell Signaling Technology

3686

WB, IP, IF
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Table 4: Oligonucleotide sequences for quantitative reverse transcription
polymerase chain reaction
Target
Forward Sequence

Reverse Sequence

Gene
5’-CGGGTCAGGTAACGGTTGAAHOXA5

5’-AGTCATGACAACATAGGCGGC-3’
3’
5’-GTCCACCACCCTGTTGCTGTA

GAPDH

5’-CAAGGTCATCCATGACAACTTTG- 3’
G-3’
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Table 5: Experimentally verified targets for miR-484 by miRWalk2.0

RefseqID

Gene

NM_000702

ATP1A2

NM_152272

CHMP7

NM_020699

GATAD2B

NM_005523

HOXA11

NM_019102

HOXA5

NM_001004317

LIN28B

NM_000254

MTR

NM_003204

NFE2L1

NM_002616

PER1

NM_024297

PHF23

NM_138300

PYGO2

NM_031459

SESN2

NM_144582

TEX261

NM_013390

TMEM2

NM_005781

TNK2

NM_017590

ZC3H7B
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